<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" id="jmv70195" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Med Virol</journal-id><journal-id journal-id-type="iso-abbrev">J Med Virol</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)1096-9071</journal-id><journal-id journal-id-type="publisher-id">JMV</journal-id><journal-title-group><journal-title>Journal of Medical Virology</journal-title></journal-title-group><issn pub-type="ppub">0146-6615</issn><issn pub-type="epub">1096-9071</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39891432</article-id><article-id pub-id-type="pmc">PMC11786146</article-id><article-id pub-id-type="doi">10.1002/jmv.70195</article-id><article-id pub-id-type="publisher-id">JMV70195</article-id><article-categories><subj-group subj-group-type="overline"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Genome&#x02010;Wide Association Analyses of HPV16 and HPV18 Seropositivity Identify Susceptibility Loci for Cervical Cancer</article-title></title-group><contrib-group><contrib id="jmv70195-cr-0001" contrib-type="author"><name><surname>Beckhaus</surname><given-names>Theresa</given-names></name><xref rid="jmv70195-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="jmv70195-cr-0002" contrib-type="author"><name><surname>Kachuri</surname><given-names>Linda</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-3226-4727</contrib-id><xref rid="jmv70195-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="jmv70195-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="jmv70195-cr-0003" contrib-type="author"><name><surname>Nakase</surname><given-names>Taishi</given-names></name><xref rid="jmv70195-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="jmv70195-cr-0004" contrib-type="author"><name><surname>Sch&#x000fc;rmann</surname><given-names>Peter</given-names></name><xref rid="jmv70195-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="jmv70195-cr-0005" contrib-type="author"><name><surname>Eisenbl&#x000e4;tter</surname><given-names>Rieke</given-names></name><xref rid="jmv70195-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="jmv70195-cr-0006" contrib-type="author"><name><surname>Geerts</surname><given-names>Maya</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-7036-1731</contrib-id><xref rid="jmv70195-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="jmv70195-cr-0007" contrib-type="author"><name><surname>B&#x000f6;hmer</surname><given-names>Gerd</given-names></name><xref rid="jmv70195-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="jmv70195-cr-0008" contrib-type="author"><name><surname>Strau&#x000df;</surname><given-names>Hans&#x02010;Georg</given-names></name><xref rid="jmv70195-aff-0005" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib id="jmv70195-cr-0009" contrib-type="author"><name><surname>Hirchenhain</surname><given-names>Christine</given-names></name><xref rid="jmv70195-aff-0006" ref-type="aff">
<sup>6</sup>
</xref></contrib><contrib id="jmv70195-cr-0010" contrib-type="author"><name><surname>Schmidmayr</surname><given-names>Monika</given-names></name><xref rid="jmv70195-aff-0007" ref-type="aff">
<sup>7</sup>
</xref></contrib><contrib id="jmv70195-cr-0011" contrib-type="author"><name><surname>M&#x000fc;ller</surname><given-names>Florian</given-names></name><xref rid="jmv70195-aff-0008" ref-type="aff">
<sup>8</sup>
</xref></contrib><contrib id="jmv70195-cr-0012" contrib-type="author"><name><surname>Fasching</surname><given-names>Peter A.</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-4885-8471</contrib-id><xref rid="jmv70195-aff-0009" ref-type="aff">
<sup>9</sup>
</xref></contrib><contrib id="jmv70195-cr-0013" contrib-type="author"><name><surname>H&#x000e4;fner</surname><given-names>Norman</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-7012-483X</contrib-id><xref rid="jmv70195-aff-0010" ref-type="aff">
<sup>10</sup>
</xref></contrib><contrib id="jmv70195-cr-0014" contrib-type="author"><name><surname>Luyten</surname><given-names>Alexander</given-names></name><xref rid="jmv70195-aff-0011" ref-type="aff">
<sup>11</sup>
</xref><xref rid="jmv70195-aff-0012" ref-type="aff">
<sup>12</sup>
</xref></contrib><contrib id="jmv70195-cr-0015" contrib-type="author"><name><surname>Jentschke</surname><given-names>Matthias</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-7613-1531</contrib-id><xref rid="jmv70195-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="jmv70195-cr-0016" contrib-type="author"><name><surname>Hillemanns</surname><given-names>Peter</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-9829-3531</contrib-id><xref rid="jmv70195-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="jmv70195-cr-0017" contrib-type="author"><name><surname>O'Mara</surname><given-names>Tracy A.</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-5436-3232</contrib-id><xref rid="jmv70195-aff-0013" ref-type="aff">
<sup>13</sup>
</xref></contrib><contrib id="jmv70195-cr-0018" contrib-type="author"><name><surname>Francis</surname><given-names>Stephen S.</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6488-6272</contrib-id><xref rid="jmv70195-aff-0014" ref-type="aff">
<sup>14</sup>
</xref></contrib><contrib id="jmv70195-cr-0019" contrib-type="author"><name><surname>Witte</surname><given-names>John S.</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-0146-1434</contrib-id><xref rid="jmv70195-aff-0003" ref-type="aff">
<sup>3</sup>
</xref><xref rid="jmv70195-aff-0015" ref-type="aff">
<sup>15</sup>
</xref></contrib><contrib id="jmv70195-cr-0020" contrib-type="author" corresp="yes"><name><surname>D&#x000f6;rk</surname><given-names>Thilo</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9458-0282</contrib-id><xref rid="jmv70195-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><address><email>Doerk.thilo@mh-hannover.de</email></address></contrib><contrib id="jmv70195-cr-0021" contrib-type="author" corresp="yes"><name><surname>Ramachandran</surname><given-names>Dhanya</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-8139-7799</contrib-id><xref rid="jmv70195-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><address><email>Ramachandran.dhanya@mh-hannover.de</email></address></contrib></contrib-group><aff id="jmv70195-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Gynaecology Research Unit, Department of Gynecology and Obstetrics</named-content>
<institution>Hannover Medical School</institution>
<city>Hannover</city>
<country country="DE">Germany</country>
</aff><aff id="jmv70195-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Department of Epidemiology and Population Health</named-content>
<institution>Stanford University School of Medicine</institution>
<city>Stanford</city>
<named-content content-type="country-part">California</named-content>
<country country="US">USA</country>
</aff><aff id="jmv70195-aff-0003">
<label>
<sup>3</sup>
</label>
<named-content content-type="organisation-division">Stanford Cancer Institute</named-content>
<institution>Stanford School of Medicine</institution>
<city>Stanford</city>
<named-content content-type="country-part">California</named-content>
<country country="US">USA</country>
</aff><aff id="jmv70195-aff-0004">
<label>
<sup>4</sup>
</label>
<institution>IZD Hannover</institution>
<city>Hannover</city>
<country country="DE">Germany</country>
</aff><aff id="jmv70195-aff-0005">
<label>
<sup>5</sup>
</label>
<named-content content-type="organisation-division">Department of Gynaecology</named-content>
<institution>Martin&#x02010;Luther University</institution>
<city>Halle&#x02010;Wittenberg</city>
<country country="DE">Germany</country>
</aff><aff id="jmv70195-aff-0006">
<label>
<sup>6</sup>
</label>
<named-content content-type="organisation-division">Department of Gynaecology</named-content>
<institution>Clinics Carl Gustav Carus, University of Dresden</institution>
<city>Dresden</city>
<country country="DE">Germany</country>
</aff><aff id="jmv70195-aff-0007">
<label>
<sup>7</sup>
</label>
<named-content content-type="organisation-division">Department of Gynaecology</named-content>
<institution>Technical University of Munich</institution>
<city>Munich</city>
<country country="DE">Germany</country>
</aff><aff id="jmv70195-aff-0008">
<label>
<sup>8</sup>
</label>
<named-content content-type="organisation-division">Martin&#x02010;Luther Hospital</named-content>
<institution>Charite University</institution>
<city>Berlin</city>
<country country="DE">Germany</country>
</aff><aff id="jmv70195-aff-0009">
<label>
<sup>9</sup>
</label>
<named-content content-type="organisation-division">Department of Gynecology and Obstetrics</named-content>
<institution>Friedrich Alexander University of Erlangen&#x02013;Nuremberg (FAU)</institution>
<city>Erlangen</city>
<country country="DE">Germany</country>
</aff><aff id="jmv70195-aff-0010">
<label>
<sup>10</sup>
</label>
<named-content content-type="organisation-division">Department of Gynecology</named-content>
<institution>Jena University Hospital, Friedrich&#x02010;Schiller&#x02010;University</institution>
<city>Jena</city>
<country country="DE">Germany</country>
</aff><aff id="jmv70195-aff-0011">
<label>
<sup>11</sup>
</label>
<named-content content-type="organisation-division">Dysplasia Unit, Department of Gynecology and Obstetrics</named-content>
<institution>Mare Klinikum</institution>
<city>Kronshagen</city>
<country country="DE">Germany</country>
</aff><aff id="jmv70195-aff-0012">
<label>
<sup>12</sup>
</label>
<named-content content-type="organisation-division">Department of Gynecology</named-content>
<institution>Wolfsburg Hospital</institution>
<city>Wolfsburg</city>
<country country="DE">Germany</country>
</aff><aff id="jmv70195-aff-0013">
<label>
<sup>13</sup>
</label>
<named-content content-type="organisation-division">Cancer Research Program</named-content>
<institution>QIMR Berghofer Medical Research Institute</institution>
<city>Brisbane</city>
<named-content content-type="country-part">Queensland</named-content>
<country country="AU">Australia</country>
</aff><aff id="jmv70195-aff-0014">
<label>
<sup>14</sup>
</label>
<named-content content-type="organisation-division">Department of Neurological Surgery, Weill Institute for Neuroscience</named-content>
<institution>University of California San Francisco</institution>
<city>San Francisco</city>
<named-content content-type="country-part">California</named-content>
<country country="US">USA</country>
</aff><aff id="jmv70195-aff-0015">
<label>
<sup>15</sup>
</label>
<named-content content-type="organisation-division">Department of Biomedical Data Science and Department of Genetics</named-content>
<institution>Stanford University School of Medicine</institution>
<city>Stanford</city>
<named-content content-type="country-part">California</named-content>
<country country="US">USA</country>
</aff><author-notes><corresp id="correspondenceTo">
<label>*</label>
<bold>Correspondence:</bold> Thilo D&#x000f6;rk (<email>Doerk.thilo@mh-hannover.de</email>)<break/>
Dhanya Ramachandran (<email>Ramachandran.dhanya@mh-hannover.de</email>)<break/>
</corresp></author-notes><pub-date pub-type="epub"><day>31</day><month>1</month><year>2025</year></pub-date><pub-date pub-type="ppub"><month>2</month><year>2025</year></pub-date><volume>97</volume><issue seq="20">2</issue><issue-id pub-id-type="doi">10.1002/jmv.v97.2</issue-id><elocation-id>e70195</elocation-id><history>
<date date-type="rev-recd"><day>29</day><month>11</month><year>2024</year></date>
<date date-type="received"><day>20</day><month>6</month><year>2024</year></date>
<date date-type="accepted"><day>13</day><month>1</month><year>2025</year></date>
</history><permissions><!--&#x000a9; 2025 Wiley Periodicals LLC.--><copyright-statement content-type="article-copyright">&#x000a9; 2025 The Author(s). <italic toggle="yes">Journal of Medical Virology</italic> published by Wiley Periodicals LLC.</copyright-statement><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="file:JMV-97-e70195.pdf"/><abstract><title>ABSTRACT</title><p>Infection by high&#x02010;risk human papillomavirus is known to exacerbate cervical cancer development. The host immune response is crucial in disease regression. Large&#x02010;scale genetic association studies for cervical cancer have identified few susceptibility variants, mainly at the human leukocyte antigen locus on chromosome 6. We hypothesized that the host immune response modifies cervical cancer risk and performed three genome&#x02010;wide association analyses for HPV16, HPV18 and HPV16/18 seropositivity in 7814, 7924, and 7924 samples from the UK Biobank, followed by validation genotyping in the German Cervigen case&#x02010;control series of cervical cancer and dysplasia. In GWAS analyses, we identified two loci associated with HPV16 seropositivity (6p21.32 and 15q26.2), two loci associated with HPV18 seropositivity (5q31.2 and 14q24.3), and one locus for HPV16 and/or HPV18 seropositivity (at 6p21.32). MAGMA gene&#x02010;based analysis identified <italic toggle="yes">HLA&#x02010;DQA1</italic> and <italic toggle="yes">HLA&#x02010;DQB1</italic> as genome&#x02010;wide significant (GWS) genes. In validation genotyping, the genome&#x02010;wide significant lead variant at 6p21.32, rs9272293 associated with overall cervical disease (OR&#x02009;=&#x02009;0.86, <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.004, 95% CI&#x02009;=&#x02009;0.78&#x02013;0.95, <italic toggle="yes">n</italic>&#x02009;=&#x02009;3710) and HPV16 positive invasive cancer (OR&#x02009;=&#x02009;0.73, <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.005, 95% CI&#x02009;=&#x02009;0.59&#x02013;0.91, <italic toggle="yes">n</italic>&#x02009;=&#x02009;1431). This variant was found to be a robust eQTL for <italic toggle="yes">HLA&#x02010;DRB1</italic>, <italic toggle="yes">HLA&#x02010;DQB1&#x02010;AS1</italic>, <italic toggle="yes">C4B</italic>, <italic toggle="yes">HLA&#x02010;DRB5</italic>, <italic toggle="yes">HLA&#x02010;DRB6</italic>, <italic toggle="yes">HLA&#x02010;DQB1</italic>, and <italic toggle="yes">HLA&#x02010;DPB1</italic> in a series of cervical epithelial tissue samples. We additionally genotyped twenty&#x02010;four HPV seropositivity variants below the GWS threshold out of which eleven variants were found to be associated with cervical disease in our cohort, suggesting that further seropositivity variants may determine cervical disease outcome. Our study identifies novel genomic risk loci that associate with HPV type&#x02010;specific cervical cancer and dysplasia risk and provides evidence for candidate genes at one of the risk loci.</p></abstract><kwd-group><kwd id="jmv70195-kwd-0001">cervical carcinoma</kwd><kwd id="jmv70195-kwd-0002">eQTL</kwd><kwd id="jmv70195-kwd-0003">human papillomavirus</kwd><kwd id="jmv70195-kwd-0004">infection</kwd><kwd id="jmv70195-kwd-0005">SNP</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source>D.R. and T.D. received funding from the H.W. &#x00026; J. Hector Stiftung (M2414). D.R. received funding from the Tumorstiftung at Hannover Medical School. M.G. received a stipend from the University of British Columbia. The Cervigen consortium was established with funding from the Bruno and Helene J&#x000f6;ster Foundation.</funding-source></award-group></funding-group><counts><fig-count count="4"/><table-count count="1"/><page-count count="15"/><word-count count="9230"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>February 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.5.3 mode:remove_FC converted:01.02.2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><def-list list-content="abbreviations"><title>Abbreviations</title><def-item><term>ANOVA</term><def><p>analysis of variance</p></def></def-item><def-item><term>CI</term><def><p>confidence interval</p></def></def-item><def-item><term>CIN</term><def><p>cervical intraepithelial neoplasia</p></def></def-item><def-item><term>DICE</term><def><p>database of immune cell expression, expression quantitative trait loci and epigenomics</p></def></def-item><def-item><term>eQTL</term><def><p>expression quantitative trait locus</p></def></def-item><def-item><term>GWS</term><def><p>genome&#x02010;wide significance</p></def></def-item><def-item><term>HPV</term><def><p>human papillomavirus</p></def></def-item><def-item><term>HSIL</term><def><p>high&#x02010;grade squamous intraepithelial lesion</p></def></def-item><def-item><term>HWE</term><def><p>Hardy&#x02010;Weinberg equilibrium</p></def></def-item><def-item><term>LD</term><def><p>linkage disequilibrium</p></def></def-item><def-item><term>LSIL</term><def><p>low&#x02010;grade squamous intraepithelial lesion</p></def></def-item><def-item><term>OR</term><def><p>odds ratio</p></def></def-item></def-list><sec id="jmv70195-sec-0010"><label>1</label><title>Introduction</title><p>Cervical cancer is the fourth most common cancer in women worldwide and approximately 2100 women in Germany currently die of cervical cancer every year [<xref rid="jmv70195-bib-0001" ref-type="bibr">1</xref>, <xref rid="jmv70195-bib-0002" ref-type="bibr">2</xref>]. Persistent HPV infection [<xref rid="jmv70195-bib-0003" ref-type="bibr">3</xref>], especially with high risk HPV types (including HPV16, HPV18, HPV31, HPV33, HPV35, HPV45, HPV52 and HPV58), is known to trigger cervical dysplasia and progression to cervical cancer, but not every woman infected with HPV develops invasive cervical cancer [<xref rid="jmv70195-bib-0004" ref-type="bibr">4</xref>]. This suggests the involvement of environmental factors (such as the use of oral contraceptives, infection with <italic toggle="yes">Chlamydia trachomatis</italic> and smoking) [<xref rid="jmv70195-bib-0005" ref-type="bibr">5</xref>] and genetic factors that may increase the risk for invasive cervical disease [<xref rid="jmv70195-bib-0006" ref-type="bibr">6</xref>]. Genome wide association studies (GWASs) have previously identified multiple susceptibility loci for cervical cancer, mainly at the human leukocyte antigen (HLA) locus on chromosome 6 that is involved in the host immune response [<xref rid="jmv70195-bib-0007" ref-type="bibr">7</xref>, <xref rid="jmv70195-bib-0008" ref-type="bibr">8</xref>, <xref rid="jmv70195-bib-0009" ref-type="bibr">9</xref>, <xref rid="jmv70195-bib-0010" ref-type="bibr">10</xref>, <xref rid="jmv70195-bib-0011" ref-type="bibr">11</xref>, <xref rid="jmv70195-bib-0012" ref-type="bibr">12</xref>]. Follow&#x02010;up studies indicated that genes from both the MHC I and II regions are modulated by cervical cancer risk variants [<xref rid="jmv70195-bib-0013" ref-type="bibr">13</xref>]. Additional non&#x02010;<italic toggle="yes">HLA</italic> susceptibility loci have been identified on chromosome 2 (<italic toggle="yes">PAX8</italic>) [<xref rid="jmv70195-bib-0010" ref-type="bibr">10</xref>], chromosome 5 (<italic toggle="yes">TERT/CLPTM1L</italic>) [<xref rid="jmv70195-bib-0011" ref-type="bibr">11</xref>], and chromosome 17 (<italic toggle="yes">GSDMB</italic>) [<xref rid="jmv70195-bib-0008" ref-type="bibr">8</xref>] that have been validated in further cohorts in meta&#x02010;analyses [<xref rid="jmv70195-bib-0006" ref-type="bibr">6</xref>, <xref rid="jmv70195-bib-0011" ref-type="bibr">11</xref>, <xref rid="jmv70195-bib-0012" ref-type="bibr">12</xref>]. The hitherto known risk variants, however, do not explain all of the genetic heritability for this disease and further susceptibility loci remain to be discovered. Given the specific role of HPV in cervical cancer, GWASs for HPV seropositivity may inform HPV&#x02010;type associated cervical cancer risk [<xref rid="jmv70195-bib-0009" ref-type="bibr">9</xref>, <xref rid="jmv70195-bib-0014" ref-type="bibr">14</xref>, <xref rid="jmv70195-bib-0015" ref-type="bibr">15</xref>]. Notably, two population&#x02010;derived GWASs have linked variants at chromosome 6 (<italic toggle="yes">HLA</italic>) and chromosome 14 (near <italic toggle="yes">VASH1</italic>) with HPV16 and HPV18 seropositivity, respectively, and these may also constitute cervical cancer risk variants [<xref rid="jmv70195-bib-0014" ref-type="bibr">14</xref>, <xref rid="jmv70195-bib-0016" ref-type="bibr">16</xref>]. In the present study we aimed to validate variants arising from HPV16 and/or HPV18 seropositivity GWASs of the UK Biobank in our German Cervigen cohort of cervical cancers and dysplasias.</p></sec><sec sec-type="methods" id="jmv70195-sec-0020"><label>2</label><title>Methods</title><sec id="jmv70195-sec-0030"><label>2.1</label><title>GWAS Analyses</title><p>GWAS summary statistics for HPV were generated in European ancestry UKB participants as previously described (Kachuri et al., 2020). GWAS analyses were conducted with approved access to UK Biobank data under application number 14105. Briefly, seropositivity was determined based on established thresholds [<xref rid="jmv70195-bib-0017" ref-type="bibr">17</xref>] for each HPV individual antigen and this was used to derive the following phenotypes: HPV16 E6/E7/L1 positive (<italic toggle="yes">n</italic>&#x02009;=&#x02009;674) versus no HPV detected (<italic toggle="yes">n</italic>&#x02009;=&#x02009;7140), HPV18 L1 positive (<italic toggle="yes">n</italic>&#x02009;=&#x02009;191) versus HPV18 negative (<italic toggle="yes">n</italic>&#x02009;=&#x02009;7733), or HPV16/18+ (HPV16 E6/E7/L1 or HPV18 L1, <italic toggle="yes">n</italic>&#x02009;=&#x02009;784) versus no HPV detected (<italic toggle="yes">n</italic>&#x02009;=&#x02009;7140) (Figure&#x000a0;<xref rid="jmv70195-suppl-0001" ref-type="supplementary-material">S1</xref>, Table&#x000a0;<xref rid="jmv70195-suppl-0002" ref-type="supplementary-material">S1</xref>). The slightly different design for HPV18 was due to the observation of several HPV16/HPV18 double positives which led us to also leave HPV16 only carriers in the HPV18&#x02010;negative group. Logistic regression models were adjusted for age at sample collection, sex, serology assay date, top 10 genetic ancestry principal components, and genotyping array. Variants at <italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;5&#x02009;&#x000d7;&#x02009;10E&#x02010;6 were submitted to LDlink (<ext-link xlink:href="https://ldlink.nih.gov/" ext-link-type="uri">https://ldlink.nih.gov/</ext-link>) and independent SNPs at (<italic toggle="yes">R</italic>
<sup>2</sup>&#x02009;&#x0003c;&#x02009;0.3) were taken for PCR validation genotyping in the German Cervigen cohort as described below. Variants with a minor allele frequency (MAF)&#x02009;&#x0003c;&#x02009;0.01 in 1000&#x02009;G EUR in LDlink, as far as known at the time of analysis, were filtered out. We noticed <italic toggle="yes">post hoc</italic> that some variants had different MAFs in dbSNP (<ext-link xlink:href="https://www.ncbi.nlm.nih.gov/snp/" ext-link-type="uri">https://www.ncbi.nlm.nih.gov/snp/</ext-link>) but they were retained since they had been genotyped. In total, 170, 193, and 677 variants across the three analyses, respectively, were identified at <italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;5&#x02009;&#x000d7;&#x02009;10E&#x02010;6. From this, 29 variants were taken for genotyping (Table&#x000a0;<xref rid="jmv70195-suppl-0003" ref-type="supplementary-material">S2</xref>).</p></sec><sec id="jmv70195-sec-0040"><label>2.2</label><title>Patient Material</title><p>In order to investigate whether variants arising from HPV seropositivity GWASs can influence the risk for cervical cancer or dysplasia, we performed a case&#x02010;control genotyping study on a total of 3710 samples from the German Cervigen consortium [<xref rid="jmv70195-bib-0018" ref-type="bibr">18</xref>]. This included 2448 cases with either invasive cervical cancer or cervical dysplasia, acquired from nine German hospitals in Hannover, Wolfsburg, Jena, Erlangen, Dresden, Halle, Munich, Berlin and Bad M&#x000fc;nder. The median age at diagnosis for cases overall was 41 years (range 17&#x02013;78 years). Additionally, 1203 cancer&#x02010; and dysplasia&#x02010;free healthy females (with unknown seropositivity status) at Hannover Medical School served as the control group. The median age for control samples was 37 years (range 18&#x02013;89 years). We utilized all cancer/dysplasia&#x02010;free controls at hand (with unknown serostatus) since the primary aim of our study was to identify cervical cancer risk associated SNPs. After obtaining informed consent, 5&#x02009;mL peripheral venous blood was drawn. The study was approved by the Ethics committee of Hannover Medical School (Votes No. 441 and 10737). All samples and data that have been used were in accordance with German medical council regulations.</p><p>A second patient&#x02010;derived cohort of 303 cervical smears from Hannover Medical School was used in eQTL analysis as explained in the section &#x0201c;Transcript analysis&#x0201d;. All these samples were cancer/dysplasia free. Genomic DNA was at hand from 280 of these cervical smears from which 78 samples were HPV positive and 202 were HPV negative. In terms of HPV positivity, 33 samples were infected by HPV16, 9 samples contained HPV18, and 36 samples had other strains of hrHPV (31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, or 68) as determined with the RealTime High Risk HPV test on the Abbott m2000 PCR system. We note a high correlation between HPV positivity and the detection of cytological lesions: 184/202 HPV&#x02010;negative samples were lesion&#x02010;negative (91%), while 54/78 HPV&#x02010;positive samples were also lesion&#x02010;positive (69%).</p></sec><sec id="jmv70195-sec-0050"><label>2.3</label><title>SNP Genotyping</title><p>Genomic DNA was isolated from peripheral white blood cells via standard phenol chloroform extraction. For lead variant rs9272293, a TaqMan assay was used for genotyping (Assay ID: C__30510445_10) the entire Cervigen case&#x02010;control series, also including samples with unknown HPV status (cervical cancer or dysplasia cases&#x02009;=&#x02009;2448, cancer&#x02010;free controls (with unknown serostatus)&#x02009;=&#x02009;1203). For the other 28 candidate variants, specific target amplification (STA) was performed on the DNA samples using pooled SNPtype assays (Fluidigm) and the 2&#x000d7; Multiplex PCR Master Mix (Qiagen). Simultaneous genotyping was then carried out using Fluidigm genotyping arrays on the BioMark HD system (Fluidigm) (Table&#x000a0;<xref rid="jmv70195-suppl-0003" ref-type="supplementary-material">S2</xref>). Cluster plots were visualized for each of these SNPs after genotyping (Figure&#x000a0;<xref rid="jmv70195-suppl-0001" ref-type="supplementary-material">S2</xref>). The 28 sub&#x02010;GWS variants were only genotyped in a part of the Cervigen cohort where HPV status was known for cases (cervical cancer or dysplasia cases&#x02009;=&#x02009;1357, cancer&#x02010;free controls (with unknown serostatus)&#x02009;=&#x02009;1203). Three variants were excluded from further evaluation (rs151043538, rs35812074 and rs551344817) due to poor or monomorphic clustering of their genotypes on the resulting scatter plots (Figure&#x000a0;<xref rid="jmv70195-suppl-0001" ref-type="supplementary-material">S2</xref>, Table&#x000a0;<xref rid="jmv70195-suppl-0004" ref-type="supplementary-material">S3</xref>). The remaining 25 variants and lead variant rs9272293 were forwarded to further statistical analyses.</p></sec><sec id="jmv70195-sec-0060"><label>2.4</label><title>Statistical Analysis</title><p>Call rates and concordance rates were calculated and the variants were tested for Hardy&#x02010;Weinberg equilibrium (HWE) using goodness&#x02010;of&#x02010;fit chi&#x02010;square tests (Table&#x000a0;<xref rid="jmv70195-suppl-0004" ref-type="supplementary-material">S3</xref>). One variant, rs12867177 failed HWE and was excluded from further statistical testing. For the remaining 25 variants, <italic toggle="yes">p</italic> values, odds ratios (OR) and 95% confidence intervals (CI) were calculated via logistic regression using the STATA v17 software (StataCorp) with case&#x02010;control status as the outcome and the variant genotype as the predictor variable. We carried out stratified analyses based on disease severity and HPV status. The cases were further divided into three groups: LSIL/low&#x02010;grade dysplasias (CIN1 combined with CIN2 patients at age&#x02009;&#x0003c;&#x02009;30&#x02009;years [CIN2&#x02009;&#x0003c;&#x02009;30]), HSIL/high&#x02010;grade dysplasias (CIN2 cases at age&#x02009;&#x02265;&#x02009;30&#x02009;years (CIN2&#x02009;&#x02265;&#x02009;30) combined with CIN3 patients), and invasive carcinomas. The group of invasive cervical carcinomas was further stratified by histological type into squamous cell carcinomas and adenocarcinomas. The subgroups HSIL and invasive carcinoma were also combined for joint analysis. For stratified analyses based on HPV type, samples were grouped into HPV16 positive, HPV18 positive, HPV16 and/or 18 positives (including both single and double positives), and &#x0201c;HPV other&#x0201d; positives (which included 12 other HPV types, detected mainly with the Abbott real time high risk HPV assay: HPV 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68). Each of these groups was compared against cancer&#x02010; and dysplasia&#x02010; free controls.</p><p>In regard of multiple testing for twenty&#x02010;five SNPs and sixteen comparisons, a Bonferroni corrected <italic toggle="yes">p</italic> value of <italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.00013 would be considered statistically significant. However, as we followed up variants from GWASs (although of HPV seropositivity), we considered association with two&#x02010;sided <italic toggle="yes">p</italic> values below 0.05 and the same direction of effect as confirmatory evidence of association with cervical disease in a particular subgroup in this genetic association study.</p></sec><sec id="jmv70195-sec-0070"><label>2.5</label><title>Bioinformatic Analysis</title><p>GWAS summary statistics were uploaded to the FUMA webtool [<xref rid="jmv70195-bib-0019" ref-type="bibr">19</xref>] for MAGMA [<xref rid="jmv70195-bib-0020" ref-type="bibr">20</xref>] analysis. Variants within a window of 25kbp were mapped to genes in the vicinity. Since variants were mapped to 19,380 protein coding genes, the Bonferroni corrected significance threshold was set at <italic toggle="yes">&#x003b1;</italic>&#x02009;=&#x02009;0.05/19380&#x02009;=&#x02009;2.58&#x02009;&#x000d7;&#x02009;10E&#x02010;6. Gene&#x02010;set enrichment analysis was run as part of MAGMA and GENE2FUNC functionality within the FUMA webtool. We additionally submitted the variants +/&#x02212; 1Mbp of the lead GWS variant (<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;5&#x02009;&#x000d7;&#x02009;10E&#x02010;8) for fine&#x02010;mapping analysis via SuSiE [<xref rid="jmv70195-bib-0021" ref-type="bibr">21</xref>] and Rsparsepro [<xref rid="jmv70195-bib-0022" ref-type="bibr">22</xref>] to identify credible sets within this locus.</p><p>In silico annotation was performed using HaploReg v4.2 [<xref rid="jmv70195-bib-0023" ref-type="bibr">23</xref>], RegulomeDB [<xref rid="jmv70195-bib-0024" ref-type="bibr">24</xref>] and ForgeDB [<xref rid="jmv70195-bib-0025" ref-type="bibr">25</xref>] for chromatin state, transcription factor binding, known eQTL effects, and changes in regulatory motifs. DNA sequences flanking 10&#x02009;bp around the lead variants (major/minor allele) were submitted to TOMTOM [<xref rid="jmv70195-bib-0026" ref-type="bibr">26</xref>] (MEME Suitev5.3.3, using the HOCOMOCOv11_full_HUMAN database) to identify allele&#x02010;specific transcription factor binding sites. In parallel, 25&#x02009;bp flanks around the SNPs of interest were submitted to the PERFECTOS&#x02010;APE webtool (<ext-link xlink:href="https://opera.autosome.org/perfectosape" ext-link-type="uri">https://opera.autosome.org/perfectosape</ext-link> using the HOCOMOCO11 HUMAN database) to determine allele&#x02010;specific transcription factor binding sites.</p><p>The lead variants were also annotated for the closest genes (+/&#x02212; 1Mbp) using UCSC Genome Browser GRCh37. Additionally, the GTEx database (v8, <ext-link xlink:href="http://www.gtexportal.org" ext-link-type="uri">www.gtexportal.org</ext-link>) was queried for known eQTLs or sQTLs in whole blood (Supplementary Table S<xref rid="jmv70195-suppl-0005" ref-type="supplementary-material">4A</xref>). Similarly, the eQTLGen consortium's eQTL database (<ext-link xlink:href="https://eqtlgen.org/cis-eqtls.html" ext-link-type="uri">https://eqtlgen.org/cis-eqtls.html</ext-link>) was queried for whole blood eQTLs as well (Table&#x000a0;<xref rid="jmv70195-suppl-0005" ref-type="supplementary-material">S4A</xref> and Table&#x000a0;<xref rid="jmv70195-suppl-0006" ref-type="supplementary-material">S5</xref>).</p><p>Since the variants arose from HPV seropositivity GWASs and may mediate the host immune response to HPV infection, we also explored possible eQTL effects in immune cells within the DICE database [<xref rid="jmv70195-bib-0027" ref-type="bibr">27</xref>] (<ext-link xlink:href="http://www.dice-database.org" ext-link-type="uri">www.dice-database.org</ext-link>) and investigated the twelve variants that showed evidence of association in the Cervigen cohort for known eQTL effects in immune cells, such as CD4 positive regulatory memory T cells, CD4 positive TH1 cells, or naive B cells.</p></sec><sec id="jmv70195-sec-0080"><label>2.6</label><title>Transcript Analysis</title><p>Total RNA was isolated from methanol&#x02010;fixed cervical tissue smears (<italic toggle="yes">n</italic>&#x02009;=&#x02009;303) via guanidinium&#x02010;phenol&#x02010;chloroform extraction with Trizol reagent (peqGOLD TriFast). From 1&#x02009;&#x000b5;g RNA of each sample, cDNA was synthesized using the Proto&#x02010;Script II First Strand cDNA Synthesis Kit (New England BioLabs). After preamplification of the cDNA samples using pooled DeltaGene assays and the Preamplification Master Mix (Fluidigm), real&#x02010;time qPCR was performed on the BioMark HD system (Fluidigm).</p><p>To study the GWS variant at the <italic toggle="yes">HLA</italic> locus on chromosome 6, rs9272293, we designed Fluidigm Deltagene assays for 36 candidate genes embedded in this region, together with epithelial cell marker genes <italic toggle="yes">KRT8</italic>, <italic toggle="yes">KRT18,</italic> and <italic toggle="yes">EPCAM</italic>, and housekeeping genes <italic toggle="yes">B2M</italic> and <italic toggle="yes">RPL13A</italic> (Table&#x000a0;<xref rid="jmv70195-suppl-0007" ref-type="supplementary-material">S6</xref>). The assays were mixed with the 2&#x000d7; SsoFast EvaGreen Super&#x02010;mix with low ROX (BioRad) to detect gene amplification curves. Two samples without cDNA were included as negative controls. Twenty&#x02010;three samples with low gene expression levels (C<sub>T</sub> above 32) for the epithelial markers <italic toggle="yes">EPCAM</italic>, <italic toggle="yes">KRT8,</italic> or <italic toggle="yes">KRT18</italic> were excluded from further statistical analysis. Normalization of target gene expression data against the housekeeping genes <italic toggle="yes">B2M</italic> and <italic toggle="yes">RPL13A</italic> was carried out with the qBASE+ software (Biogazelle). Outliers were removed from the dataset using the ROUT method on Graphpad Prism v10.1 (Dotmatics).</p><p>Genomic DNA from the same samples (<italic toggle="yes">n</italic>&#x02009;=&#x02009;280) was isolated in a magnetic bead&#x02010;based purification process on the M24 SP instrument (Abbott) and subjected to SNP genotyping. For eQTL analysis, the log10 normalized gene expression values of 280 cDNA samples were analyzed for association with the genotypes of the lead variant rs9272293 in matching DNA samples. Genotypes and gene expression levels were investigated under an allelic model in all samples (overall) as well as after stratification based on HPV status (HPV positive or HPV negative sub&#x02010;groups). For some genes with low levels of gene expression, an additional Pearson's correlation test was performed in GraphPad Prism v10 to explore whether the genotype correlates with the presence or absence (C<sub>T</sub> above 32) of gene transcripts (Supplementary Table <xref rid="jmv70195-suppl-0008" ref-type="supplementary-material">S7</xref>). For the comparison of three groups, ANOVA was applied, and p values were also reported after a linear test for trend. Multiple testing correction threshold (Bonferroni method) was applied as 36 genes were tested to be eQTLs (<italic toggle="yes">&#x003b1;</italic>&#x02009;=&#x02009;0.05/36&#x02009;=&#x02009;1.4&#x02009;&#x000d7;&#x02009;10E&#x02010;3) and only SNP&#x02010;gene pairs passing this threshold were considered to be robust eQTLs. For gene&#x02010;gene correlation analysis, Pearson's R was calculated in GraphPad Prism v10.</p></sec></sec><sec sec-type="results" id="jmv70195-sec-0090"><label>3</label><title>Results</title><sec id="jmv70195-sec-0100"><label>3.1</label><title>GWAS Outcomes</title><p>GWAS analysis for HPV16 seropositivity identified three variants at GWS, rs9272293 G&#x02009;&#x0003e;&#x02009;A at 6p21.32 (OR&#x02009;=&#x02009;0.71 (allele A), SE&#x02009;=&#x02009;0.06; <italic toggle="yes">p</italic>&#x02009;=&#x02009;3.93&#x02009;&#x000d7;&#x02009;10E&#x02010;8) and rs1828768 (T&#x02009;&#x0003e;&#x02009;C) and rs991757 (A&#x02009;&#x0003e;&#x02009;G) at 15q26.2 (OR&#x02009;=&#x02009;0.69 (allele T), SE&#x02009;=&#x02009;0.07; <italic toggle="yes">p</italic>&#x02009;=&#x02009;2.02&#x02009;&#x000d7;&#x02009;10E&#x02010;8; and OR&#x02009;=&#x02009;0.69 (allele A), SE&#x02009;=&#x02009;0.07; <italic toggle="yes">p</italic>&#x02009;=&#x02009;2.59&#x02009;&#x000d7;&#x02009;10E&#x02010;8, respectively) (Figure&#x000a0;<xref rid="jmv70195-fig-0001" ref-type="fig">1A</xref>), whereas for HPV18 seropositivity two variants (rs142237244 G&#x02009;&#x0003e;&#x02009;A at 5q31.2 with OR&#x02009;=&#x02009;4.95 (allele A), SE&#x02009;=&#x02009;0.29; <italic toggle="yes">p</italic>&#x02009;=&#x02009;3.43&#x02009;&#x000d7;&#x02009;10E&#x02010;8; and rs4243652 at 14q24.3 with OR&#x02009;=&#x02009;3.14 (allele G), SE&#x02009;=&#x02009;0.19; <italic toggle="yes">p</italic>&#x02009;=&#x02009;5.84&#x02009;&#x000d7;&#x02009;10E&#x02010;10) were genome&#x02010;wide significant (Figure&#x000a0;<xref rid="jmv70195-fig-0001" ref-type="fig">1B</xref>). For HPV16 and/or HPV18 seropositivity, we found two genome&#x02010;wide significant variants (rs9272293 with OR&#x02009;=&#x02009;0.72 (allele A), SE&#x02009;=&#x02009;0.06; <italic toggle="yes">p</italic>&#x02009;=&#x02009;1.49&#x02009;&#x000d7;&#x02009;10E&#x02010;8 and rs17612669 at 6p21.32 with OR&#x02009;=&#x02009;0.73 (allele G), SE&#x02009;=&#x02009;0.06; <italic toggle="yes">p</italic>&#x02009;=&#x02009;4.64&#x02009;&#x000d7;&#x02009;10E&#x02010;8) (Figure&#x000a0;<xref rid="jmv70195-fig-0001" ref-type="fig">1C</xref>). In genome&#x02010;wide gene&#x02010;based analysis in MAGMA, <italic toggle="yes">HLA&#x02010;DQA1</italic> and <italic toggle="yes">HLA&#x02010;DQB1</italic> were identified as genome&#x02010;wide significant regions, corroborating the signals at 6p21.32 (Figure&#x000a0;<xref rid="jmv70195-fig-0001" ref-type="fig">1D&#x02013;F</xref>). In the gene&#x02010;set enrichment analysis in MAGMA, no gene sets were detected with a Bonferroni corrected p&#x02010;value below 0.05 in either of the three GWAS data sets (Table&#x000a0;<xref rid="jmv70195-suppl-0009" ref-type="supplementary-material">S8A</xref>). However, in the GENE2FUNC functionality of FUMA, in gene set enrichment analysis, Immunologic signatures (MsigDB c7), 117, 0, and 63 gene sets were identified as enriched in the HPV16, HPV18, and HPV16/18 seropositivity analysis, respectively (Table&#x000a0;<xref rid="jmv70195-suppl-0009" ref-type="supplementary-material">S8B</xref>). All the gene set enrichment results from GENE2FUNC for each of the GWASs are noted in Table&#x000a0;<xref rid="jmv70195-suppl-0009" ref-type="supplementary-material">S8C</xref>. In fine&#x02010;mapping analysis using SuSiE [<xref rid="jmv70195-bib-0021" ref-type="bibr">21</xref>], only one 95% credible set was identified with the lead variant rs9272293 having the highest PIP of 0.066. This credible set included 889 variants (Table&#x000a0;<xref rid="jmv70195-suppl-0010" ref-type="supplementary-material">S9A</xref>, Figure&#x000a0;<xref rid="jmv70195-suppl-0001" ref-type="supplementary-material">S3</xref>). Fine&#x02010;mapping using Rsparsepro [<xref rid="jmv70195-bib-0022" ref-type="bibr">22</xref>] identified a single credible set of 814 variants, with the lead variant rs9272293 having the highest PIP of 0.099 (Table&#x000a0;<xref rid="jmv70195-suppl-0010" ref-type="supplementary-material">S9B</xref>).</p><fig position="float" fig-type="Figure" id="jmv70195-fig-0001"><label>Figure 1</label><caption><p>GWAS plots for HPV seropositivity GWASs. &#x02212;log10 p values from the GWAS summary statistics are plotted on the <italic toggle="yes">y</italic> axis for (A) HPV16 seropositivity, (B) HPV18 seropositivity and (C) HPV16 and/or 18 seropositivity in Manhattan plots. Chromosomes are represented on the <italic toggle="yes">x</italic> axis. The dotted red line is set at the genome&#x02010;wide significance level of 5&#x02009;&#x000d7;&#x02009;10E&#x02010;8. Furthermore, &#x02212;log10 <italic toggle="yes">p</italic> values after MAGMA gene&#x02010;based analysis are shown with Manhattan plots for (D) HPV16 seropositivity, (E) HPV18 seropositivity and (F) HPV16 and/or 18 seropositivity. Since SNPs were mapped to 19,380 protein coding genes, the red line indicates <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.05/19380&#x02009;=&#x02009;2.58&#x02009;&#x000d7;&#x02009;10E&#x02010;6.</p></caption><graphic xlink:href="JMV-97-e70195-g004" position="anchor" id="jats-graphic-1"/></fig></sec><sec id="jmv70195-sec-0110"><label>3.2</label><title>Cervical Cancer Case&#x02010;Control Genotyping</title><p>Among the GWS variants, rs9272293 and rs17612669 are moderately linked with <italic toggle="yes">R</italic>
<sup>2</sup>&#x02009;=&#x02009;0.45 in 1000G EUR and highly linked in UKB EUR GRCh37 (<italic toggle="yes">R<sup>2</sup>
</italic> = 0.89), and the former was taken for TaqMan genotyping due to the significant association with HPV16 only and HPV16/HPV18 in GWAS results. Also, rs991757 and rs1828768 are in high linkage disequilibrium (<italic toggle="yes">R</italic>
<sup>2</sup>&#x02009;=&#x02009;0.99 1KG EUR) and the former was taken forward for PCR&#x02010;based genotyping. rs142237244 was not genotyped due to its low MAF in Europeans (0.0096 in 1000&#x02009;G), and rs4243652 had already been described as successfully replicated in our previous cervical cancer case&#x02010;control study [<xref rid="jmv70195-bib-0015" ref-type="bibr">15</xref>]. We thus forwarded rs9272293 and rs991757 as two independent GWS signals to the validation stage.</p><p>We also added further sub&#x02010;genome&#x02010;wide significant variants to test their potential role in cervical cancer. From 170, 193, and 677 variants, respectively, at <italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;5&#x02009;&#x000d7;&#x02009;10E&#x02010;6 (summary statistics provided in Table&#x000a0;<xref rid="jmv70195-suppl-0002" ref-type="supplementary-material">S1</xref>), we filtered 27 variants for further PCR&#x02010;based case&#x02010;control genotyping in the Cervigen cohort (Figure&#x000a0;<xref rid="jmv70195-suppl-0001" ref-type="supplementary-material">S2</xref>, Table&#x000a0;<xref rid="jmv70195-suppl-0003" ref-type="supplementary-material">S2</xref>).</p><p>We genotyped up to 2484 cases and 1226 controls of the Cervigen series (Table&#x000a0;<xref rid="jmv70195-tbl-0001" ref-type="table">1</xref>, Table&#x000a0;<xref rid="jmv70195-suppl-0011" ref-type="supplementary-material">S10</xref>). Four variants were removed due to poor clustering or failing HWE, leaving 23 sub&#x02010;genome&#x02010;wide variants in addition to the two GWS signals for the association analyses. For these 25 candidate variants, call rates were at least 95% (Table&#x000a0;<xref rid="jmv70195-suppl-0004" ref-type="supplementary-material">S3</xref>). Approximately 10% of all samples were repeated and concordance rates ranged between 83.9% and 100% (Table&#x000a0;<xref rid="jmv70195-suppl-0004" ref-type="supplementary-material">S3</xref>).</p><table-wrap position="float" id="jmv70195-tbl-0001" content-type="Table"><label>Table 1</label><caption><p>Results after logistic regression analyses from the genetic case&#x02010;control study.</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" align="left" span="1"/><col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" align="center" span="1"/><col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" align="center" span="1"/><col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" align="center" span="1"/><col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" align="center" span="1"/><col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" align="center" span="1"/><col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" align="center" span="1"/><col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" align="center" span="1"/><col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" align="center" span="1"/><col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" align="center" span="1"/><col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" align="center" span="1"/><col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" align="center" span="1"/><col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" align="center" span="1"/><thead valign="bottom"><tr valign="bottom"><th align="left" valign="bottom" rowspan="1" colspan="1">Variant ID</th><th colspan="4" style="border-bottom:solid 1px #000000" align="center" valign="bottom" rowspan="1">rs9272293 (HPV16+, HPV16/18+)</th><th colspan="4" style="border-bottom:solid 1px #000000" align="center" valign="bottom" rowspan="1">rs17867660 (HPV16+, HPV16/18+)</th><th colspan="4" style="border-bottom:solid 1px #000000" align="center" valign="bottom" rowspan="1">rs6084436 (HPV16+, HPV16/18+)</th></tr><tr valign="bottom" style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Stratum</th><th align="center" valign="bottom" rowspan="1" colspan="1">Controls</th><th align="center" valign="bottom" rowspan="1" colspan="1">Cases</th><th align="center" valign="bottom" rowspan="1" colspan="1">OR (95% CI)</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic> value</th><th align="center" valign="bottom" rowspan="1" colspan="1">Controls</th><th align="center" valign="bottom" rowspan="1" colspan="1">Cases</th><th align="center" valign="bottom" rowspan="1" colspan="1">OR(95%CI)</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic> value</th><th align="center" valign="bottom" rowspan="1" colspan="1">Controls</th><th align="center" valign="bottom" rowspan="1" colspan="1">Cases</th><th align="center" valign="bottom" rowspan="1" colspan="1">OR (95% CI)</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic> value</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Overall</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">1226</td><td align="center" valign="top" rowspan="1" colspan="1">2484</td><td align="center" valign="top" rowspan="1" colspan="1">0.86 (0.78&#x02013;0.95)</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>0.004</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">1073</td><td align="center" valign="top" rowspan="1" colspan="1">1310</td><td align="center" valign="top" rowspan="1" colspan="1">0.97 (0.87&#x02013;1.09)</td><td align="center" valign="top" rowspan="1" colspan="1">0.604</td><td align="center" valign="top" rowspan="1" colspan="1">1063</td><td align="center" valign="top" rowspan="1" colspan="1">1292</td><td align="center" valign="top" rowspan="1" colspan="1">1.08 (0.86&#x02013;1.34)</td><td align="center" valign="top" rowspan="1" colspan="1">0.515</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Dysplasia</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">1226</td><td align="center" valign="top" rowspan="1" colspan="1">1373</td><td align="center" valign="top" rowspan="1" colspan="1">0.90 (0.80&#x02013;1.00)</td><td align="center" valign="top" rowspan="1" colspan="1">0.055</td><td align="center" valign="top" rowspan="1" colspan="1">1073</td><td align="center" valign="top" rowspan="1" colspan="1">868</td><td align="center" valign="top" rowspan="1" colspan="1">1.05 (0.92&#x02013;1.19)</td><td align="center" valign="top" rowspan="1" colspan="1">0.452</td><td align="center" valign="top" rowspan="1" colspan="1">1063</td><td align="center" valign="top" rowspan="1" colspan="1">831</td><td align="center" valign="top" rowspan="1" colspan="1">1.04 (0.81&#x02013;1.34)</td><td align="center" valign="top" rowspan="1" colspan="1">0.74</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">LSIL</td><td align="center" valign="top" rowspan="1" colspan="1">1226</td><td align="center" valign="top" rowspan="1" colspan="1">228</td><td align="center" valign="top" rowspan="1" colspan="1">0.93 (0.76&#x02013;1.13)</td><td align="center" valign="top" rowspan="1" colspan="1">0.455</td><td align="center" valign="top" rowspan="1" colspan="1">1073</td><td align="center" valign="top" rowspan="1" colspan="1">196</td><td align="center" valign="top" rowspan="1" colspan="1">0.99 (0.79&#x02013;1.23)</td><td align="center" valign="top" rowspan="1" colspan="1">0.907</td><td align="center" valign="top" rowspan="1" colspan="1">1063</td><td align="center" valign="top" rowspan="1" colspan="1">189</td><td align="center" valign="top" rowspan="1" colspan="1">1.22 (0.81&#x02013;1.84)</td><td align="center" valign="top" rowspan="1" colspan="1">0.331</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HSIL</td><td align="center" valign="top" rowspan="1" colspan="1">1226</td><td align="center" valign="top" rowspan="1" colspan="1">1145</td><td align="center" valign="top" rowspan="1" colspan="1">0.89 (0.79&#x02013;1.00)</td><td align="center" valign="top" rowspan="1" colspan="1">0.054</td><td align="center" valign="top" rowspan="1" colspan="1">1073</td><td align="center" valign="top" rowspan="1" colspan="1">672</td><td align="center" valign="top" rowspan="1" colspan="1">1.07 (0.93&#x02013;1.23)</td><td align="center" valign="top" rowspan="1" colspan="1">0.339</td><td align="center" valign="top" rowspan="1" colspan="1">1063</td><td align="center" valign="top" rowspan="1" colspan="1">642</td><td align="center" valign="top" rowspan="1" colspan="1">0.99 (0.76&#x02013;1.30)</td><td align="center" valign="top" rowspan="1" colspan="1">0.961</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Invasive</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">1226</td><td align="center" valign="top" rowspan="1" colspan="1">1075</td><td align="center" valign="top" rowspan="1" colspan="1">0.83 (0.74&#x02013;0.93)</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>0.002</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">1073</td><td align="center" valign="top" rowspan="1" colspan="1">442</td><td align="center" valign="top" rowspan="1" colspan="1">0.83 (0.70&#x02013;0.97)</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>0.02</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">1063</td><td align="center" valign="top" rowspan="1" colspan="1">461</td><td align="center" valign="top" rowspan="1" colspan="1">1.14 (0.85&#x02013;1.53)</td><td align="center" valign="top" rowspan="1" colspan="1">0.383</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Adenocarcinoma</td><td align="center" valign="top" rowspan="1" colspan="1">1226</td><td align="center" valign="top" rowspan="1" colspan="1">186</td><td align="center" valign="top" rowspan="1" colspan="1">0.78 (0.62&#x02013;0.97)</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>0.026</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">1073</td><td align="center" valign="top" rowspan="1" colspan="1">71</td><td align="center" valign="top" rowspan="1" colspan="1">0.73 (0.51&#x02013;1.04)</td><td align="center" valign="top" rowspan="1" colspan="1">0.078</td><td align="center" valign="top" rowspan="1" colspan="1">1063</td><td align="center" valign="top" rowspan="1" colspan="1">74</td><td align="center" valign="top" rowspan="1" colspan="1">1.21 (0.65&#x02013;2.23)</td><td align="center" valign="top" rowspan="1" colspan="1">0.55</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Squamous carcinoma</td><td align="center" valign="top" rowspan="1" colspan="1">1226</td><td align="center" valign="top" rowspan="1" colspan="1">698</td><td align="center" valign="top" rowspan="1" colspan="1">0.87 (0.76&#x02013;0.99)</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>0.038</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">1073</td><td align="center" valign="top" rowspan="1" colspan="1">340</td><td align="center" valign="top" rowspan="1" colspan="1">0.85 (0.71&#x02013;1.01)</td><td align="center" valign="top" rowspan="1" colspan="1">0.065</td><td align="center" valign="top" rowspan="1" colspan="1">1063</td><td align="center" valign="top" rowspan="1" colspan="1">364</td><td align="center" valign="top" rowspan="1" colspan="1">1.10 (0.79&#x02013;1.52)</td><td align="center" valign="top" rowspan="1" colspan="1">0.583</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Invasive</bold>&#x02009;+&#x02009;<bold>HSIL combined</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">1226</td><td align="center" valign="top" rowspan="1" colspan="1">2220</td><td align="center" valign="top" rowspan="1" colspan="1">0.86 (0.78&#x02013;0.95)</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>0.003</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">1073</td><td align="center" valign="top" rowspan="1" colspan="1">1114</td><td align="center" valign="top" rowspan="1" colspan="1">0.97 (0.86&#x02013;1.09)</td><td align="center" valign="top" rowspan="1" colspan="1">0.582</td><td align="center" valign="top" rowspan="1" colspan="1">1063</td><td align="center" valign="top" rowspan="1" colspan="1">1103</td><td align="center" valign="top" rowspan="1" colspan="1">1.05 (0.84&#x02013;1.33)</td><td align="center" valign="top" rowspan="1" colspan="1">0.663</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>HPV16&#x02009;+&#x02009;ve Overall</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">1226</td><td align="center" valign="top" rowspan="1" colspan="1">329</td><td align="center" valign="top" rowspan="1" colspan="1">0.76 (0.64&#x02013;0.91)</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>0.003</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">1073</td><td align="center" valign="top" rowspan="1" colspan="1">321</td><td align="center" valign="top" rowspan="1" colspan="1">0.95 (0.80&#x02013;1.14)</td><td align="center" valign="top" rowspan="1" colspan="1">0.586</td><td align="center" valign="top" rowspan="1" colspan="1">1063</td><td align="center" valign="top" rowspan="1" colspan="1">301</td><td align="center" valign="top" rowspan="1" colspan="1">1.38 (1.00&#x02013;1.92)</td><td align="center" valign="top" rowspan="1" colspan="1">0.054</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HPV16&#x02009;+&#x02009;ve Invasive&#x02009;+&#x02009;HSIL</td><td align="center" valign="top" rowspan="1" colspan="1">1226</td><td align="center" valign="top" rowspan="1" colspan="1">308</td><td align="center" valign="top" rowspan="1" colspan="1">0.76 (0.64&#x02013;0.91)</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>0.004</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">1073</td><td align="center" valign="top" rowspan="1" colspan="1">299</td><td align="center" valign="top" rowspan="1" colspan="1">0.95 (0.79&#x02013;1.14)</td><td align="center" valign="top" rowspan="1" colspan="1">0.575</td><td align="center" valign="top" rowspan="1" colspan="1">1063</td><td align="center" valign="top" rowspan="1" colspan="1">286</td><td align="center" valign="top" rowspan="1" colspan="1">1.35 (0.96&#x02013;1.89)</td><td align="center" valign="top" rowspan="1" colspan="1">0.084</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>HPV18&#x02009;+&#x02009;ve Overall</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">1226</td><td align="center" valign="top" rowspan="1" colspan="1">116</td><td align="center" valign="top" rowspan="1" colspan="1">0.82 (0.62&#x02013;1.08)</td><td align="center" valign="top" rowspan="1" colspan="1">0.164</td><td align="center" valign="top" rowspan="1" colspan="1">1073</td><td align="center" valign="top" rowspan="1" colspan="1">121</td><td align="center" valign="top" rowspan="1" colspan="1">0.95 (0.72&#x02013;1.24)</td><td align="center" valign="top" rowspan="1" colspan="1">0.7</td><td align="center" valign="top" rowspan="1" colspan="1">1063</td><td align="center" valign="top" rowspan="1" colspan="1">102</td><td align="center" valign="top" rowspan="1" colspan="1">1.49 (0.91&#x02013;2.45)</td><td align="center" valign="top" rowspan="1" colspan="1">0.113</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HPV18&#x02009;+&#x02009;ve Invasive&#x02009;+&#x02009;HSIL</td><td align="center" valign="top" rowspan="1" colspan="1">1226</td><td align="center" valign="top" rowspan="1" colspan="1">109</td><td align="center" valign="top" rowspan="1" colspan="1">0.83 (0.62&#x02013;1.10)</td><td align="center" valign="top" rowspan="1" colspan="1">0.194</td><td align="center" valign="top" rowspan="1" colspan="1">1073</td><td align="center" valign="top" rowspan="1" colspan="1">113</td><td align="center" valign="top" rowspan="1" colspan="1">0.98 (0.74&#x02013;1.30)</td><td align="center" valign="top" rowspan="1" colspan="1">0.882</td><td align="center" valign="top" rowspan="1" colspan="1">1063</td><td align="center" valign="top" rowspan="1" colspan="1">98</td><td align="center" valign="top" rowspan="1" colspan="1">1.39 (0.83&#x02013;2.33)</td><td align="center" valign="top" rowspan="1" colspan="1">0.215</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>HPV16/18&#x02009;+&#x02009;ve Overall</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">1226</td><td align="center" valign="top" rowspan="1" colspan="1">420</td><td align="center" valign="top" rowspan="1" colspan="1">0.78 (0.66&#x02013;0.91)</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>0.002</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">1073</td><td align="center" valign="top" rowspan="1" colspan="1">413</td><td align="center" valign="top" rowspan="1" colspan="1">0.94 (0.80&#x02013;1.11)</td><td align="center" valign="top" rowspan="1" colspan="1">0.485</td><td align="center" valign="top" rowspan="1" colspan="1">1063</td><td align="center" valign="top" rowspan="1" colspan="1">386</td><td align="center" valign="top" rowspan="1" colspan="1">1.41 (1.05&#x02013;1.90)</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>0.023</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HPV16/18&#x02009;+&#x02009;ve Invasive&#x02009;+&#x02009;HSIL</td><td align="center" valign="top" rowspan="1" colspan="1">1226</td><td align="center" valign="top" rowspan="1" colspan="1">394</td><td align="center" valign="top" rowspan="1" colspan="1">0.77 (0.66&#x02013;0.91)</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>0.002</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">1073</td><td align="center" valign="top" rowspan="1" colspan="1">386</td><td align="center" valign="top" rowspan="1" colspan="1">0.94 (0.79&#x02013;1.11)</td><td align="center" valign="top" rowspan="1" colspan="1">0.445</td><td align="center" valign="top" rowspan="1" colspan="1">1063</td><td align="center" valign="top" rowspan="1" colspan="1">367</td><td align="center" valign="top" rowspan="1" colspan="1">1.36 (1.00&#x02013;1.85)</td><td align="center" valign="top" rowspan="1" colspan="1">0.051</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>HPV (other)&#x02009;+&#x02009;ve Overall</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">1226</td><td align="center" valign="top" rowspan="1" colspan="1">95</td><td align="center" valign="top" rowspan="1" colspan="1">0.74 (0.54&#x02013;1.00)</td><td align="center" valign="top" rowspan="1" colspan="1">0.054</td><td align="center" valign="top" rowspan="1" colspan="1">1073</td><td align="center" valign="top" rowspan="1" colspan="1">90</td><td align="center" valign="top" rowspan="1" colspan="1">1.19 (0.88&#x02013;1.62)</td><td align="center" valign="top" rowspan="1" colspan="1">0.256</td><td align="center" valign="top" rowspan="1" colspan="1">1063</td><td align="center" valign="top" rowspan="1" colspan="1">82</td><td align="center" valign="top" rowspan="1" colspan="1">1.08 (0.58&#x02013;2.00)</td><td align="center" valign="top" rowspan="1" colspan="1">0.807</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HPV (other)&#x02009;+&#x02009;ve Invasive&#x02009;+&#x02009;HSIL</td><td align="center" valign="top" rowspan="1" colspan="1">1226</td><td align="center" valign="top" rowspan="1" colspan="1">71</td><td align="center" valign="top" rowspan="1" colspan="1">0.77 (0.55&#x02013;1.10)</td><td align="center" valign="top" rowspan="1" colspan="1">0.147</td><td align="center" valign="top" rowspan="1" colspan="1">1073</td><td align="center" valign="top" rowspan="1" colspan="1">68</td><td align="center" valign="top" rowspan="1" colspan="1">1.23 (0.87&#x02013;1.75)</td><td align="center" valign="top" rowspan="1" colspan="1">0.241</td><td align="center" valign="top" rowspan="1" colspan="1">1063</td><td align="center" valign="top" rowspan="1" colspan="1">63</td><td align="center" valign="top" rowspan="1" colspan="1">0.93 (0.44&#x02013;1.94)</td><td align="center" valign="top" rowspan="1" colspan="1">0.837</td></tr></tbody></table><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" align="left" span="1"/><col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" align="center" span="1"/><col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" align="center" span="1"/><col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" align="center" span="1"/><col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" align="center" span="1"/><col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" align="center" span="1"/><col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" align="center" span="1"/><col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" align="center" span="1"/><col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" align="center" span="1"/><col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" align="center" span="1"/><col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" align="center" span="1"/><col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" align="center" span="1"/><col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" align="center" span="1"/><thead valign="bottom"><tr valign="bottom"><th align="left" valign="bottom" rowspan="1" colspan="1">Variant ID</th><th colspan="4" style="border-bottom:solid 1px #000000" align="center" valign="bottom" rowspan="1">rs11658042 (HPV16+)</th><th colspan="4" style="border-bottom:solid 1px #000000" align="center" valign="bottom" rowspan="1">rs742625 (HPV16+)</th><th colspan="4" style="border-bottom:solid 1px #000000" align="center" valign="bottom" rowspan="1">rs115851441 (HPV18+)</th></tr><tr valign="bottom" style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Stratum</th><th align="center" valign="bottom" rowspan="1" colspan="1">Controls</th><th align="center" valign="bottom" rowspan="1" colspan="1">Cases</th><th align="center" valign="bottom" rowspan="1" colspan="1">OR (95% CI)</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic> value</th><th align="center" valign="bottom" rowspan="1" colspan="1">Controls</th><th align="center" valign="bottom" rowspan="1" colspan="1">Cases</th><th align="center" valign="bottom" rowspan="1" colspan="1">OR (95% CI)</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic> value</th><th align="center" valign="bottom" rowspan="1" colspan="1">Controls</th><th align="center" valign="bottom" rowspan="1" colspan="1">Cases</th><th align="center" valign="bottom" rowspan="1" colspan="1">OR (95% CI)</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic> value</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Overall</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">1067</td><td align="center" valign="top" rowspan="1" colspan="1">1328</td><td align="center" valign="top" rowspan="1" colspan="1">0.95 (0.80&#x02013;1.13)</td><td align="center" valign="top" rowspan="1" colspan="1">0.558</td><td align="center" valign="top" rowspan="1" colspan="1">1200</td><td align="center" valign="top" rowspan="1" colspan="1">1354</td><td align="center" valign="top" rowspan="1" colspan="1">0.53 (0.32&#x02013;0.88)</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>0.014</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">1070</td><td align="center" valign="top" rowspan="1" colspan="1">1349</td><td align="center" valign="top" rowspan="1" colspan="1">0.71 (0.52&#x02013;0.97)</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>0.031</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Dysplasia</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">1067</td><td align="center" valign="top" rowspan="1" colspan="1">873</td><td align="center" valign="top" rowspan="1" colspan="1">1.00 (0.83&#x02013;1.21)</td><td align="center" valign="top" rowspan="1" colspan="1">0.996</td><td align="center" valign="top" rowspan="1" colspan="1">1200</td><td align="center" valign="top" rowspan="1" colspan="1">879</td><td align="center" valign="top" rowspan="1" colspan="1">0.56 (0.31&#x02013;0.99)</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>0.045</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">1070</td><td align="center" valign="top" rowspan="1" colspan="1">880</td><td align="center" valign="top" rowspan="1" colspan="1">0.73 (0.52&#x02013;1.03)</td><td align="center" valign="top" rowspan="1" colspan="1">0.073</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">LSIL</td><td align="center" valign="top" rowspan="1" colspan="1">1067</td><td align="center" valign="top" rowspan="1" colspan="1">199</td><td align="center" valign="top" rowspan="1" colspan="1">1.01 (0.74&#x02013;1.40)</td><td align="center" valign="top" rowspan="1" colspan="1">0.929</td><td align="center" valign="top" rowspan="1" colspan="1">1200</td><td align="center" valign="top" rowspan="1" colspan="1">198</td><td align="center" valign="top" rowspan="1" colspan="1">0.73 (0.29&#x02013;1.88)</td><td align="center" valign="top" rowspan="1" colspan="1">0.516</td><td align="center" valign="top" rowspan="1" colspan="1">1070</td><td align="center" valign="top" rowspan="1" colspan="1">198</td><td align="center" valign="top" rowspan="1" colspan="1">0.36 (0.16&#x02013;0.83)</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>0.016</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HSIL</td><td align="center" valign="top" rowspan="1" colspan="1">1067</td><td align="center" valign="top" rowspan="1" colspan="1">674</td><td align="center" valign="top" rowspan="1" colspan="1">1.00 (0.81&#x02013;1.22)</td><td align="center" valign="top" rowspan="1" colspan="1">0.972</td><td align="center" valign="top" rowspan="1" colspan="1">1200</td><td align="center" valign="top" rowspan="1" colspan="1">681</td><td align="center" valign="top" rowspan="1" colspan="1">0.51 (0.26&#x02013;0.97)</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>0.041</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">1070</td><td align="center" valign="top" rowspan="1" colspan="1">682</td><td align="center" valign="top" rowspan="1" colspan="1">0.84 (0.59&#x02013;1.20)</td><td align="center" valign="top" rowspan="1" colspan="1">0.343</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Invasive</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">1067</td><td align="center" valign="top" rowspan="1" colspan="1">455</td><td align="center" valign="top" rowspan="1" colspan="1">0.85 (0.66&#x02013;1.09)</td><td align="center" valign="top" rowspan="1" colspan="1">0.193</td><td align="center" valign="top" rowspan="1" colspan="1">1200</td><td align="center" valign="top" rowspan="1" colspan="1">475</td><td align="center" valign="top" rowspan="1" colspan="1">0.48 (0.23&#x02013;1.04)</td><td align="center" valign="top" rowspan="1" colspan="1">0.063</td><td align="center" valign="top" rowspan="1" colspan="1">1070</td><td align="center" valign="top" rowspan="1" colspan="1">469</td><td align="center" valign="top" rowspan="1" colspan="1">0.69 (0.44&#x02013;1.06)</td><td align="center" valign="top" rowspan="1" colspan="1">0.09</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Adenocarcinoma</td><td align="center" valign="top" rowspan="1" colspan="1">1067</td><td align="center" valign="top" rowspan="1" colspan="1">72</td><td align="center" valign="top" rowspan="1" colspan="1">1.48 (0.93&#x02013;2.35)</td><td align="center" valign="top" rowspan="1" colspan="1">0.099</td><td align="center" valign="top" rowspan="1" colspan="1">1200</td><td align="center" valign="top" rowspan="1" colspan="1">75</td><td align="center" valign="top" rowspan="1" colspan="1">0.77 (0.18&#x02013;3.27)</td><td align="center" valign="top" rowspan="1" colspan="1">0.728</td><td align="center" valign="top" rowspan="1" colspan="1">1070</td><td align="center" valign="top" rowspan="1" colspan="1">75</td><td align="center" valign="top" rowspan="1" colspan="1">0.96 (0.42&#x02013;2.21)</td><td align="center" valign="top" rowspan="1" colspan="1">0.926</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Squamous carcinoma</td><td align="center" valign="top" rowspan="1" colspan="1">1067</td><td align="center" valign="top" rowspan="1" colspan="1">352</td><td align="center" valign="top" rowspan="1" colspan="1">0.71 (0.53&#x02013;0.95)</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>0.019</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">1200</td><td align="center" valign="top" rowspan="1" colspan="1">368</td><td align="center" valign="top" rowspan="1" colspan="1">0.39 (0.15&#x02013;0.99)</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>0.048</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">1070</td><td align="center" valign="top" rowspan="1" colspan="1">363</td><td align="center" valign="top" rowspan="1" colspan="1">0.69 (0.43&#x02013;1.12)</td><td align="center" valign="top" rowspan="1" colspan="1">0.13</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Invasive</bold>&#x02009;+&#x02009;<bold>HSIL combined</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">1067</td><td align="center" valign="top" rowspan="1" colspan="1">1129</td><td align="center" valign="top" rowspan="1" colspan="1">0.94 (0.78&#x02013;1.12)</td><td align="center" valign="top" rowspan="1" colspan="1">0.487</td><td align="center" valign="top" rowspan="1" colspan="1">1200</td><td align="center" valign="top" rowspan="1" colspan="1">1156</td><td align="center" valign="top" rowspan="1" colspan="1">0.50 (0.29&#x02013;0.85)</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>0.011</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">1070</td><td align="center" valign="top" rowspan="1" colspan="1">1151</td><td align="center" valign="top" rowspan="1" colspan="1">0.78 (0.57&#x02013;1.06)</td><td align="center" valign="top" rowspan="1" colspan="1">0.113</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>HPV16&#x02009;+&#x02009;ve Overall</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">1067</td><td align="center" valign="top" rowspan="1" colspan="1">330</td><td align="center" valign="top" rowspan="1" colspan="1">0.87 (0.66&#x02013;1.15)</td><td align="center" valign="top" rowspan="1" colspan="1">0.32</td><td align="center" valign="top" rowspan="1" colspan="1">1200</td><td align="center" valign="top" rowspan="1" colspan="1">350</td><td align="center" valign="top" rowspan="1" colspan="1">0.49 (0.21&#x02013;1.17)</td><td align="center" valign="top" rowspan="1" colspan="1">0.109</td><td align="center" valign="top" rowspan="1" colspan="1">1070</td><td align="center" valign="top" rowspan="1" colspan="1">345</td><td align="center" valign="top" rowspan="1" colspan="1">0.87 (0.55&#x02013;1.36)</td><td align="center" valign="top" rowspan="1" colspan="1">0.537</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HPV16&#x02009;+&#x02009;ve Invasive&#x02009;+&#x02009;HSIL</td><td align="center" valign="top" rowspan="1" colspan="1">1067</td><td align="center" valign="top" rowspan="1" colspan="1">308</td><td align="center" valign="top" rowspan="1" colspan="1">0.88 (0.67&#x02013;1.17)</td><td align="center" valign="top" rowspan="1" colspan="1">0.387</td><td align="center" valign="top" rowspan="1" colspan="1">1200</td><td align="center" valign="top" rowspan="1" colspan="1">328</td><td align="center" valign="top" rowspan="1" colspan="1">0.44 (0.17&#x02013;1.12)</td><td align="center" valign="top" rowspan="1" colspan="1">0.084</td><td align="center" valign="top" rowspan="1" colspan="1">1070</td><td align="center" valign="top" rowspan="1" colspan="1">323</td><td align="center" valign="top" rowspan="1" colspan="1">0.89 (0.56&#x02013;1.41)</td><td align="center" valign="top" rowspan="1" colspan="1">0.619</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>HPV18&#x02009;+&#x02009;ve Overall</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">1067</td><td align="center" valign="top" rowspan="1" colspan="1">121</td><td align="center" valign="top" rowspan="1" colspan="1">0.94 (0.62&#x02013;1.42)</td><td align="center" valign="top" rowspan="1" colspan="1">0.762</td><td align="center" valign="top" rowspan="1" colspan="1">1200</td><td align="center" valign="top" rowspan="1" colspan="1">121</td><td align="center" valign="top" rowspan="1" colspan="1">.</td><td align="center" valign="top" rowspan="1" colspan="1">.</td><td align="center" valign="top" rowspan="1" colspan="1">1070</td><td align="center" valign="top" rowspan="1" colspan="1">120</td><td align="center" valign="top" rowspan="1" colspan="1">0.70 (0.32&#x02013;1.51)</td><td align="center" valign="top" rowspan="1" colspan="1">0.362</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HPV18&#x02009;+&#x02009;ve Invasive&#x02009;+&#x02009;HSIL</td><td align="center" valign="top" rowspan="1" colspan="1">1067</td><td align="center" valign="top" rowspan="1" colspan="1">113</td><td align="center" valign="top" rowspan="1" colspan="1">1.02 (0.67&#x02013;1.55)</td><td align="center" valign="top" rowspan="1" colspan="1">0.937</td><td align="center" valign="top" rowspan="1" colspan="1">1200</td><td align="center" valign="top" rowspan="1" colspan="1">113</td><td align="center" valign="top" rowspan="1" colspan="1">.</td><td align="center" valign="top" rowspan="1" colspan="1">.</td><td align="center" valign="top" rowspan="1" colspan="1">1070</td><td align="center" valign="top" rowspan="1" colspan="1">112</td><td align="center" valign="top" rowspan="1" colspan="1">0.53 (0.22&#x02013;1.32)</td><td align="center" valign="top" rowspan="1" colspan="1">0.173</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>HPV16/18&#x02009;+&#x02009;ve Overall</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">1067</td><td align="center" valign="top" rowspan="1" colspan="1">422</td><td align="center" valign="top" rowspan="1" colspan="1">0.86 (0.67&#x02013;1.11)</td><td align="center" valign="top" rowspan="1" colspan="1">0.249</td><td align="center" valign="top" rowspan="1" colspan="1">1200</td><td align="center" valign="top" rowspan="1" colspan="1">442</td><td align="center" valign="top" rowspan="1" colspan="1">0.39 (0.16&#x02013;0.92)</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>0.032</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">1070</td><td align="center" valign="top" rowspan="1" colspan="1">436</td><td align="center" valign="top" rowspan="1" colspan="1">0.85 (0.56&#x02013;1.29)</td><td align="center" valign="top" rowspan="1" colspan="1">0.445</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HPV16/18&#x02009;+&#x02009;ve Invasive&#x02009;+&#x02009;HSIL</td><td align="center" valign="top" rowspan="1" colspan="1">1067</td><td align="center" valign="top" rowspan="1" colspan="1">395</td><td align="center" valign="top" rowspan="1" colspan="1">0.88 (0.68&#x02013;1.14)</td><td align="center" valign="top" rowspan="1" colspan="1">0.351</td><td align="center" valign="top" rowspan="1" colspan="1">1200</td><td align="center" valign="top" rowspan="1" colspan="1">415</td><td align="center" valign="top" rowspan="1" colspan="1">0.34 (0.14&#x02013;0.88)</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>0.026</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">1070</td><td align="center" valign="top" rowspan="1" colspan="1">409</td><td align="center" valign="top" rowspan="1" colspan="1">0.82 (0.53&#x02013;1.26)</td><td align="center" valign="top" rowspan="1" colspan="1">0.362</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>HPV(other)&#x02009;+&#x02009;ve Overall</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">1067</td><td align="center" valign="top" rowspan="1" colspan="1">91</td><td align="center" valign="top" rowspan="1" colspan="1">0.80 (0.49&#x02013;1.32)</td><td align="center" valign="top" rowspan="1" colspan="1">0.383</td><td align="center" valign="top" rowspan="1" colspan="1">1200</td><td align="center" valign="top" rowspan="1" colspan="1">91</td><td align="center" valign="top" rowspan="1" colspan="1">0.31 (0.04&#x02013;2.31)</td><td align="center" valign="top" rowspan="1" colspan="1">0.255</td><td align="center" valign="top" rowspan="1" colspan="1">1070</td><td align="center" valign="top" rowspan="1" colspan="1">91</td><td align="center" valign="top" rowspan="1" colspan="1">0.39 (0.12&#x02013;1.25)</td><td align="center" valign="top" rowspan="1" colspan="1">0.113</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HPV(other)&#x02009;+&#x02009;ve Invasive&#x02009;+&#x02009;HSIL</td><td align="center" valign="top" rowspan="1" colspan="1">1067</td><td align="center" valign="top" rowspan="1" colspan="1">69</td><td align="center" valign="top" rowspan="1" colspan="1">0.78 (0.44&#x02013;1.37)</td><td align="center" valign="top" rowspan="1" colspan="1">0.384</td><td align="center" valign="top" rowspan="1" colspan="1">1200</td><td align="center" valign="top" rowspan="1" colspan="1">69</td><td align="center" valign="top" rowspan="1" colspan="1">0.42 (0.06&#x02013;3.07)</td><td align="center" valign="top" rowspan="1" colspan="1">0.389</td><td align="center" valign="top" rowspan="1" colspan="1">1070</td><td align="center" valign="top" rowspan="1" colspan="1">69</td><td align="center" valign="top" rowspan="1" colspan="1">0.17 (0.02&#x02013;1.24)</td><td align="center" valign="top" rowspan="1" colspan="1">0.081</td></tr></tbody></table><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" align="left" span="1"/><col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" align="center" span="1"/><col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" align="center" span="1"/><col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" align="center" span="1"/><col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" align="center" span="1"/><col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" align="center" span="1"/><col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" align="center" span="1"/><col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" align="center" span="1"/><col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" align="center" span="1"/><col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" align="center" span="1"/><col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" align="center" span="1"/><col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" align="center" span="1"/><col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" align="center" span="1"/><thead valign="bottom"><tr valign="bottom"><th align="left" valign="bottom" rowspan="1" colspan="1">Variant ID</th><th colspan="4" style="border-bottom:solid 1px #000000" align="center" valign="bottom" rowspan="1">rs114272671 (HPV18+)</th><th colspan="4" style="border-bottom:solid 1px #000000" align="center" valign="bottom" rowspan="1">rs12207703 (HPV18+)</th><th colspan="4" style="border-bottom:solid 1px #000000" align="center" valign="bottom" rowspan="1">rs72808738 (HPV18+)</th></tr><tr valign="bottom" style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Stratum</th><th align="center" valign="bottom" rowspan="1" colspan="1">Controls</th><th align="center" valign="bottom" rowspan="1" colspan="1">Cases</th><th align="center" valign="bottom" rowspan="1" colspan="1">OR (95% CI)</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic> value</th><th align="center" valign="bottom" rowspan="1" colspan="1">Controls</th><th align="center" valign="bottom" rowspan="1" colspan="1">Cases</th><th align="center" valign="bottom" rowspan="1" colspan="1">OR (95% CI)</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic> value</th><th align="center" valign="bottom" rowspan="1" colspan="1">Controls</th><th align="center" valign="bottom" rowspan="1" colspan="1">Cases</th><th align="center" valign="bottom" rowspan="1" colspan="1">OR (95% CI)</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic> value</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Overall</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">1203</td><td align="center" valign="top" rowspan="1" colspan="1">1349</td><td align="center" valign="top" rowspan="1" colspan="1">0.89 (0.61&#x02013;1.30)</td><td align="center" valign="top" rowspan="1" colspan="1">0.543</td><td align="center" valign="top" rowspan="1" colspan="1">1071</td><td align="center" valign="top" rowspan="1" colspan="1">1316</td><td align="center" valign="top" rowspan="1" colspan="1">0.95 (0.83&#x02013;1.09)</td><td align="center" valign="top" rowspan="1" colspan="1">0.464</td><td align="center" valign="top" rowspan="1" colspan="1">1071</td><td align="center" valign="top" rowspan="1" colspan="1">1355</td><td align="center" valign="top" rowspan="1" colspan="1">0.94 (0.66&#x02013;1.34)</td><td align="center" valign="top" rowspan="1" colspan="1">0.743</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Dysplasia</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">1203</td><td align="center" valign="top" rowspan="1" colspan="1">878</td><td align="center" valign="top" rowspan="1" colspan="1">1.05 (0.70&#x02013;1.57)</td><td align="center" valign="top" rowspan="1" colspan="1">0.823</td><td align="center" valign="top" rowspan="1" colspan="1">1071</td><td align="center" valign="top" rowspan="1" colspan="1">867</td><td align="center" valign="top" rowspan="1" colspan="1">1.01 (0.87&#x02013;1.17)</td><td align="center" valign="top" rowspan="1" colspan="1">0.942</td><td align="center" valign="top" rowspan="1" colspan="1">1071</td><td align="center" valign="top" rowspan="1" colspan="1">880</td><td align="center" valign="top" rowspan="1" colspan="1">0.92 (0.62&#x02013;1.36)</td><td align="center" valign="top" rowspan="1" colspan="1">0.674</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">LSIL</td><td align="center" valign="top" rowspan="1" colspan="1">1203</td><td align="center" valign="top" rowspan="1" colspan="1">199</td><td align="center" valign="top" rowspan="1" colspan="1">0.99 (0.48&#x02013;2.03)</td><td align="center" valign="top" rowspan="1" colspan="1">0.975</td><td align="center" valign="top" rowspan="1" colspan="1">1071</td><td align="center" valign="top" rowspan="1" colspan="1">195</td><td align="center" valign="top" rowspan="1" colspan="1">1.09 (0.86&#x02013;1.40)</td><td align="center" valign="top" rowspan="1" colspan="1">0.474</td><td align="center" valign="top" rowspan="1" colspan="1">1071</td><td align="center" valign="top" rowspan="1" colspan="1">199</td><td align="center" valign="top" rowspan="1" colspan="1">1.04 (0.55&#x02013;1.98)</td><td align="center" valign="top" rowspan="1" colspan="1">0.909</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HSIL</td><td align="center" valign="top" rowspan="1" colspan="1">1203</td><td align="center" valign="top" rowspan="1" colspan="1">679</td><td align="center" valign="top" rowspan="1" colspan="1">1.06 (0.69&#x02013;1.65)</td><td align="center" valign="top" rowspan="1" colspan="1">0.779</td><td align="center" valign="top" rowspan="1" colspan="1">1071</td><td align="center" valign="top" rowspan="1" colspan="1">672</td><td align="center" valign="top" rowspan="1" colspan="1">0.98 (0.83&#x02013;1.15)</td><td align="center" valign="top" rowspan="1" colspan="1">0.804</td><td align="center" valign="top" rowspan="1" colspan="1">1071</td><td align="center" valign="top" rowspan="1" colspan="1">681</td><td align="center" valign="top" rowspan="1" colspan="1">0.88 (0.58&#x02013;1.36)</td><td align="center" valign="top" rowspan="1" colspan="1">0.576</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Invasive</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">1203</td><td align="center" valign="top" rowspan="1" colspan="1">471</td><td align="center" valign="top" rowspan="1" colspan="1">0.59 (0.32&#x02013;1.09)</td><td align="center" valign="top" rowspan="1" colspan="1">0.095</td><td align="center" valign="top" rowspan="1" colspan="1">1071</td><td align="center" valign="top" rowspan="1" colspan="1">449</td><td align="center" valign="top" rowspan="1" colspan="1">0.85 (0.71&#x02013;1.03)</td><td align="center" valign="top" rowspan="1" colspan="1">0.09</td><td align="center" valign="top" rowspan="1" colspan="1">1071</td><td align="center" valign="top" rowspan="1" colspan="1">475</td><td align="center" valign="top" rowspan="1" colspan="1">0.99 (0.62&#x02013;1.58)</td><td align="center" valign="top" rowspan="1" colspan="1">0.963</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Adenocarcinoma</td><td align="center" valign="top" rowspan="1" colspan="1">1203</td><td align="center" valign="top" rowspan="1" colspan="1">74</td><td align="center" valign="top" rowspan="1" colspan="1">1.51 (0.59&#x02013;3.90)</td><td align="center" valign="top" rowspan="1" colspan="1">0.392</td><td align="center" valign="top" rowspan="1" colspan="1">1071</td><td align="center" valign="top" rowspan="1" colspan="1">72</td><td align="center" valign="top" rowspan="1" colspan="1">0.90 (0.6&#x02013;1.36)</td><td align="center" valign="top" rowspan="1" colspan="1">0.627</td><td align="center" valign="top" rowspan="1" colspan="1">1071</td><td align="center" valign="top" rowspan="1" colspan="1">75</td><td align="center" valign="top" rowspan="1" colspan="1">2.80 (1.44&#x02013;5.41)</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>0.002</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Squamous carcinoma</td><td align="center" valign="top" rowspan="1" colspan="1">1203</td><td align="center" valign="top" rowspan="1" colspan="1">365</td><td align="center" valign="top" rowspan="1" colspan="1">0.41 (0.18&#x02013;0.90)</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>0.027</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">1071</td><td align="center" valign="top" rowspan="1" colspan="1">345</td><td align="center" valign="top" rowspan="1" colspan="1">0.78 (0.64&#x02013;0.97)</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>0.022</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">1071</td><td align="center" valign="top" rowspan="1" colspan="1">367</td><td align="center" valign="top" rowspan="1" colspan="1">0.62 (0.33&#x02013;1.15)</td><td align="center" valign="top" rowspan="1" colspan="1">0.127</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Invasive</bold>&#x02009;+&#x02009;<bold>HSIL combined</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">1203</td><td align="center" valign="top" rowspan="1" colspan="1">1150</td><td align="center" valign="top" rowspan="1" colspan="1">0.87 (0.59&#x02013;1.30)</td><td align="center" valign="top" rowspan="1" colspan="1">0.499</td><td align="center" valign="top" rowspan="1" colspan="1">1071</td><td align="center" valign="top" rowspan="1" colspan="1">1121</td><td align="center" valign="top" rowspan="1" colspan="1">0.93 (0.81&#x02013;1.07)</td><td align="center" valign="top" rowspan="1" colspan="1">0.285</td><td align="center" valign="top" rowspan="1" colspan="1">1071</td><td align="center" valign="top" rowspan="1" colspan="1">1156</td><td align="center" valign="top" rowspan="1" colspan="1">0.93 (0.64&#x02013;1.34)</td><td align="center" valign="top" rowspan="1" colspan="1">0.684</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>HPV16&#x02009;+&#x02009;ve Overall</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">1203</td><td align="center" valign="top" rowspan="1" colspan="1">347</td><td align="center" valign="top" rowspan="1" colspan="1">0.43 (0.19&#x02013;0.95)</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>0.038</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">1071</td><td align="center" valign="top" rowspan="1" colspan="1">325</td><td align="center" valign="top" rowspan="1" colspan="1">0.99 (0.80&#x02013;1.21)</td><td align="center" valign="top" rowspan="1" colspan="1">0.903</td><td align="center" valign="top" rowspan="1" colspan="1">1071</td><td align="center" valign="top" rowspan="1" colspan="1">349</td><td align="center" valign="top" rowspan="1" colspan="1">0.76 (0.43&#x02013;1.35)</td><td align="center" valign="top" rowspan="1" colspan="1">0.352</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HPV16&#x02009;+&#x02009;ve Invasive&#x02009;+&#x02009;HSIL</td><td align="center" valign="top" rowspan="1" colspan="1">1203</td><td align="center" valign="top" rowspan="1" colspan="1">325</td><td align="center" valign="top" rowspan="1" colspan="1">0.46 (0.21&#x02013;1.02)</td><td align="center" valign="top" rowspan="1" colspan="1">0.056</td><td align="center" valign="top" rowspan="1" colspan="1">1071</td><td align="center" valign="top" rowspan="1" colspan="1">304</td><td align="center" valign="top" rowspan="1" colspan="1">0.95 (0.77&#x02013;1.18)</td><td align="center" valign="top" rowspan="1" colspan="1">0.666</td><td align="center" valign="top" rowspan="1" colspan="1">1071</td><td align="center" valign="top" rowspan="1" colspan="1">327</td><td align="center" valign="top" rowspan="1" colspan="1">0.81 (0.46&#x02013;1.44)</td><td align="center" valign="top" rowspan="1" colspan="1">0.473</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>HPV18&#x02009;+&#x02009;ve Overall</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">1203</td><td align="center" valign="top" rowspan="1" colspan="1">121</td><td align="center" valign="top" rowspan="1" colspan="1">0.35 (0.08&#x02013;1.46)</td><td align="center" valign="top" rowspan="1" colspan="1">0.149</td><td align="center" valign="top" rowspan="1" colspan="1">1071</td><td align="center" valign="top" rowspan="1" colspan="1">118</td><td align="center" valign="top" rowspan="1" colspan="1">0.88 (0.64&#x02013;1.22)</td><td align="center" valign="top" rowspan="1" colspan="1">0.445</td><td align="center" valign="top" rowspan="1" colspan="1">1071</td><td align="center" valign="top" rowspan="1" colspan="1">120</td><td align="center" valign="top" rowspan="1" colspan="1">1.25 (0.60&#x02013;2.62)</td><td align="center" valign="top" rowspan="1" colspan="1">0.552</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HPV18&#x02009;+&#x02009;ve Invasive&#x02009;+&#x02009;HSIL</td><td align="center" valign="top" rowspan="1" colspan="1">1203</td><td align="center" valign="top" rowspan="1" colspan="1">113</td><td align="center" valign="top" rowspan="1" colspan="1">0.19 (0.03&#x02013;1.36)</td><td align="center" valign="top" rowspan="1" colspan="1">0.098</td><td align="center" valign="top" rowspan="1" colspan="1">1071</td><td align="center" valign="top" rowspan="1" colspan="1">111</td><td align="center" valign="top" rowspan="1" colspan="1">0.88 (0.63&#x02013;1.23)</td><td align="center" valign="top" rowspan="1" colspan="1">0.471</td><td align="center" valign="top" rowspan="1" colspan="1">1071</td><td align="center" valign="top" rowspan="1" colspan="1">112</td><td align="center" valign="top" rowspan="1" colspan="1">1.17 (0.54&#x02013;2.56)</td><td align="center" valign="top" rowspan="1" colspan="1">0.689</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>HPV16/18&#x02009;+&#x02009;ve Overall</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">1203</td><td align="center" valign="top" rowspan="1" colspan="1">439</td><td align="center" valign="top" rowspan="1" colspan="1">0.44 (0.21&#x02013;0.89)</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>0.023</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">1071</td><td align="center" valign="top" rowspan="1" colspan="1">417</td><td align="center" valign="top" rowspan="1" colspan="1">0.92 (0.77&#x02013;1.12)</td><td align="center" valign="top" rowspan="1" colspan="1">0.412</td><td align="center" valign="top" rowspan="1" colspan="1">1071</td><td align="center" valign="top" rowspan="1" colspan="1">441</td><td align="center" valign="top" rowspan="1" colspan="1">0.90 (0.55&#x02013;1.47)</td><td align="center" valign="top" rowspan="1" colspan="1">0.667</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HPV16/18&#x02009;+&#x02009;ve Invasive&#x02009;+&#x02009;HSIL</td><td align="center" valign="top" rowspan="1" colspan="1">1203</td><td align="center" valign="top" rowspan="1" colspan="1">412</td><td align="center" valign="top" rowspan="1" colspan="1">0.41 (0.20&#x02013;0.88)</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>0.021</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">1071</td><td align="center" valign="top" rowspan="1" colspan="1">391</td><td align="center" valign="top" rowspan="1" colspan="1">0.90 (0.74&#x02013;1.09)</td><td align="center" valign="top" rowspan="1" colspan="1">0.278</td><td align="center" valign="top" rowspan="1" colspan="1">1071</td><td align="center" valign="top" rowspan="1" colspan="1">414</td><td align="center" valign="top" rowspan="1" colspan="1">0.91 (0.55&#x02013;1.50)</td><td align="center" valign="top" rowspan="1" colspan="1">0.713</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>HPV (other)&#x02009;+&#x02009;ve Overall</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">1203</td><td align="center" valign="top" rowspan="1" colspan="1">91</td><td align="center" valign="top" rowspan="1" colspan="1">0.71 (0.22&#x02013;2.32)</td><td align="center" valign="top" rowspan="1" colspan="1">0.573</td><td align="center" valign="top" rowspan="1" colspan="1">1071</td><td align="center" valign="top" rowspan="1" colspan="1">88</td><td align="center" valign="top" rowspan="1" colspan="1">1.15 (0.81&#x02013;1.62)</td><td align="center" valign="top" rowspan="1" colspan="1">0.445</td><td align="center" valign="top" rowspan="1" colspan="1">1071</td><td align="center" valign="top" rowspan="1" colspan="1">90</td><td align="center" valign="top" rowspan="1" colspan="1">0.63 (0.20&#x02013;2.00)</td><td align="center" valign="top" rowspan="1" colspan="1">0.433</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HPV (other)&#x02009;+&#x02009;ve Invasive&#x02009;+&#x02009;HSIL</td><td align="center" valign="top" rowspan="1" colspan="1">1203</td><td align="center" valign="top" rowspan="1" colspan="1">69</td><td align="center" valign="top" rowspan="1" colspan="1">0.62 (0.15&#x02013;2.61)</td><td align="center" valign="top" rowspan="1" colspan="1">0.517</td><td align="center" valign="top" rowspan="1" colspan="1">1071</td><td align="center" valign="top" rowspan="1" colspan="1">67</td><td align="center" valign="top" rowspan="1" colspan="1">1.12 (0.75&#x02013;1.67)</td><td align="center" valign="top" rowspan="1" colspan="1">0.57</td><td align="center" valign="top" rowspan="1" colspan="1">1071</td><td align="center" valign="top" rowspan="1" colspan="1">68</td><td align="center" valign="top" rowspan="1" colspan="1">0.56 (0.14&#x02013;2.27)</td><td align="center" valign="top" rowspan="1" colspan="1">0.413</td></tr></tbody></table><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" align="left" span="1"/><col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" align="center" span="1"/><col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" align="center" span="1"/><col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" align="center" span="1"/><col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" align="center" span="1"/><col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" align="center" span="1"/><col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" align="center" span="1"/><col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" align="center" span="1"/><col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" align="center" span="1"/><col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" align="center" span="1"/><col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" align="center" span="1"/><col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" align="center" span="1"/><col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" align="center" span="1"/><thead valign="bottom"><tr valign="bottom"><th align="left" valign="bottom" rowspan="1" colspan="1">Variant ID</th><th colspan="4" style="border-bottom:solid 1px #000000" align="center" valign="bottom" rowspan="1">rs76710445 (HPV18+)</th><th colspan="4" style="border-bottom:solid 1px #000000" align="center" valign="bottom" rowspan="1">rs79316639 (HPV18+)</th><th colspan="4" style="border-bottom:solid 1px #000000" align="center" valign="bottom" rowspan="1">rs13288372 (HPV16/18+)</th></tr><tr valign="bottom" style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Stratum</th><th align="center" valign="bottom" rowspan="1" colspan="1">Controls</th><th align="center" valign="bottom" rowspan="1" colspan="1">Cases</th><th align="center" valign="bottom" rowspan="1" colspan="1">OR (95% CI)</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic> value</th><th align="center" valign="bottom" rowspan="1" colspan="1">Controls</th><th align="center" valign="bottom" rowspan="1" colspan="1">Cases</th><th align="center" valign="bottom" rowspan="1" colspan="1">OR (95% CI)</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic> value</th><th align="center" valign="bottom" rowspan="1" colspan="1">Controls</th><th align="center" valign="bottom" rowspan="1" colspan="1">Cases</th><th align="center" valign="bottom" rowspan="1" colspan="1">OR(95%CI)</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic> value</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Overall</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">1202</td><td align="center" valign="top" rowspan="1" colspan="1">1352</td><td align="center" valign="top" rowspan="1" colspan="1">0.74 (0.51&#x02013;1.05)</td><td align="center" valign="top" rowspan="1" colspan="1">0.093</td><td align="center" valign="top" rowspan="1" colspan="1">906</td><td align="center" valign="top" rowspan="1" colspan="1">1349</td><td align="center" valign="top" rowspan="1" colspan="1">1.54 (1.01&#x02013;2.34)</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>0.043</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">1064</td><td align="center" valign="top" rowspan="1" colspan="1">1310</td><td align="center" valign="top" rowspan="1" colspan="1">1.15 (1.01&#x02013;1.31)</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>0.032</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Dysplasia</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">1202</td><td align="center" valign="top" rowspan="1" colspan="1">879</td><td align="center" valign="top" rowspan="1" colspan="1">0.64 (0.42&#x02013;0.98)</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>0.04</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">906</td><td align="center" valign="top" rowspan="1" colspan="1">881</td><td align="center" valign="top" rowspan="1" colspan="1">1.57 (1.01&#x02013;2.46)</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>0.046</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">1064</td><td align="center" valign="top" rowspan="1" colspan="1">860</td><td align="center" valign="top" rowspan="1" colspan="1">1.18 (1.02&#x02013;1.35)</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>0.024</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">LSIL</td><td align="center" valign="top" rowspan="1" colspan="1">1202</td><td align="center" valign="top" rowspan="1" colspan="1">198</td><td align="center" valign="top" rowspan="1" colspan="1">0.25 (0.08&#x02013;0.81)</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>0.021</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">906</td><td align="center" valign="top" rowspan="1" colspan="1">199</td><td align="center" valign="top" rowspan="1" colspan="1">1.14 (0.53&#x02013;2.45)</td><td align="center" valign="top" rowspan="1" colspan="1">0.745</td><td align="center" valign="top" rowspan="1" colspan="1">1064</td><td align="center" valign="top" rowspan="1" colspan="1">194</td><td align="center" valign="top" rowspan="1" colspan="1">0.98 (0.77&#x02013;1.25)</td><td align="center" valign="top" rowspan="1" colspan="1">0.863</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HSIL</td><td align="center" valign="top" rowspan="1" colspan="1">1202</td><td align="center" valign="top" rowspan="1" colspan="1">681</td><td align="center" valign="top" rowspan="1" colspan="1">0.76 (0.49&#x02013;1.17)</td><td align="center" valign="top" rowspan="1" colspan="1">0.214</td><td align="center" valign="top" rowspan="1" colspan="1">906</td><td align="center" valign="top" rowspan="1" colspan="1">682</td><td align="center" valign="top" rowspan="1" colspan="1">1.70 (1.07&#x02013;2.70)</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>0.025</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">1064</td><td align="center" valign="top" rowspan="1" colspan="1">666</td><td align="center" valign="top" rowspan="1" colspan="1">1.24 (1.06&#x02013;1.44)</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>0.006</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Invasive</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">1202</td><td align="center" valign="top" rowspan="1" colspan="1">473</td><td align="center" valign="top" rowspan="1" colspan="1">0.92 (0.57&#x02013;1.47)</td><td align="center" valign="top" rowspan="1" colspan="1">0.716</td><td align="center" valign="top" rowspan="1" colspan="1">906</td><td align="center" valign="top" rowspan="1" colspan="1">468</td><td align="center" valign="top" rowspan="1" colspan="1">1.46 (0.86&#x02013;2.48)</td><td align="center" valign="top" rowspan="1" colspan="1">0.166</td><td align="center" valign="top" rowspan="1" colspan="1">1064</td><td align="center" valign="top" rowspan="1" colspan="1">450</td><td align="center" valign="top" rowspan="1" colspan="1">1.10 (0.92&#x02013;1.31)</td><td align="center" valign="top" rowspan="1" colspan="1">0.28</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Adenocarcinoma</td><td align="center" valign="top" rowspan="1" colspan="1">1202</td><td align="center" valign="top" rowspan="1" colspan="1">74</td><td align="center" valign="top" rowspan="1" colspan="1">1.19 (0.46&#x02013;3.05)</td><td align="center" valign="top" rowspan="1" colspan="1">0.717</td><td align="center" valign="top" rowspan="1" colspan="1">906</td><td align="center" valign="top" rowspan="1" colspan="1">74</td><td align="center" valign="top" rowspan="1" colspan="1">1.89 (0.74&#x02013;4.83)</td><td align="center" valign="top" rowspan="1" colspan="1">0.182</td><td align="center" valign="top" rowspan="1" colspan="1">1064</td><td align="center" valign="top" rowspan="1" colspan="1">73</td><td align="center" valign="top" rowspan="1" colspan="1">1.10 (0.76&#x02013;1.60)</td><td align="center" valign="top" rowspan="1" colspan="1">0.602</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Squamous carcinoma</td><td align="center" valign="top" rowspan="1" colspan="1">1202</td><td align="center" valign="top" rowspan="1" colspan="1">366</td><td align="center" valign="top" rowspan="1" colspan="1">0.90 (0.53&#x02013;1.52)</td><td align="center" valign="top" rowspan="1" colspan="1">0.69</td><td align="center" valign="top" rowspan="1" colspan="1">906</td><td align="center" valign="top" rowspan="1" colspan="1">361</td><td align="center" valign="top" rowspan="1" colspan="1">1.41 (0.79&#x02013;2.52)</td><td align="center" valign="top" rowspan="1" colspan="1">0.242</td><td align="center" valign="top" rowspan="1" colspan="1">1064</td><td align="center" valign="top" rowspan="1" colspan="1">345</td><td align="center" valign="top" rowspan="1" colspan="1">1.12 (0.92&#x02013;1.35)</td><td align="center" valign="top" rowspan="1" colspan="1">0.249</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>Invasive</bold>&#x02009;+&#x02009;<bold>HSIL combined</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">1202</td><td align="center" valign="top" rowspan="1" colspan="1">1154</td><td align="center" valign="top" rowspan="1" colspan="1">0.82 (0.57&#x02013;1.18)</td><td align="center" valign="top" rowspan="1" colspan="1">0.29</td><td align="center" valign="top" rowspan="1" colspan="1">906</td><td align="center" valign="top" rowspan="1" colspan="1">1150</td><td align="center" valign="top" rowspan="1" colspan="1">1.61 (1.05&#x02013;2.46)</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>0.029</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">1064</td><td align="center" valign="top" rowspan="1" colspan="1">1116</td><td align="center" valign="top" rowspan="1" colspan="1">1.18 (1.04&#x02013;1.35)</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>0.013</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>HPV16&#x02009;+&#x02009;ve Overall</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">1202</td><td align="center" valign="top" rowspan="1" colspan="1">350</td><td align="center" valign="top" rowspan="1" colspan="1">0.89 (0.52&#x02013;1.52)</td><td align="center" valign="top" rowspan="1" colspan="1">0.669</td><td align="center" valign="top" rowspan="1" colspan="1">906</td><td align="center" valign="top" rowspan="1" colspan="1">346</td><td align="center" valign="top" rowspan="1" colspan="1">1.53 (0.88&#x02013;2.68)</td><td align="center" valign="top" rowspan="1" colspan="1">0.135</td><td align="center" valign="top" rowspan="1" colspan="1">1064</td><td align="center" valign="top" rowspan="1" colspan="1">326</td><td align="center" valign="top" rowspan="1" colspan="1">1.07 (0.88&#x02013;1.30)</td><td align="center" valign="top" rowspan="1" colspan="1">0.478</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HPV16&#x02009;+&#x02009;ve Invasive&#x02009;+&#x02009;HSIL</td><td align="center" valign="top" rowspan="1" colspan="1">1202</td><td align="center" valign="top" rowspan="1" colspan="1">328</td><td align="center" valign="top" rowspan="1" colspan="1">0.90 (0.52&#x02013;1.55)</td><td align="center" valign="top" rowspan="1" colspan="1">0.698</td><td align="center" valign="top" rowspan="1" colspan="1">906</td><td align="center" valign="top" rowspan="1" colspan="1">324</td><td align="center" valign="top" rowspan="1" colspan="1">1.55 (0.88&#x02013;2.73)</td><td align="center" valign="top" rowspan="1" colspan="1">0.132</td><td align="center" valign="top" rowspan="1" colspan="1">1064</td><td align="center" valign="top" rowspan="1" colspan="1">304</td><td align="center" valign="top" rowspan="1" colspan="1">1.11 (0.91&#x02013;1.35)</td><td align="center" valign="top" rowspan="1" colspan="1">0.32</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>HPV18&#x02009;+&#x02009;ve Overall</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">1202</td><td align="center" valign="top" rowspan="1" colspan="1">121</td><td align="center" valign="top" rowspan="1" colspan="1">0.86 (0.36&#x02013;2.02)</td><td align="center" valign="top" rowspan="1" colspan="1">0.723</td><td align="center" valign="top" rowspan="1" colspan="1">906</td><td align="center" valign="top" rowspan="1" colspan="1">121</td><td align="center" valign="top" rowspan="1" colspan="1">1.17 (0.46&#x02013;2.97)</td><td align="center" valign="top" rowspan="1" colspan="1">0.746</td><td align="center" valign="top" rowspan="1" colspan="1">1064</td><td align="center" valign="top" rowspan="1" colspan="1">120</td><td align="center" valign="top" rowspan="1" colspan="1">1.04 (0.77&#x02013;1.41)</td><td align="center" valign="top" rowspan="1" colspan="1">0.784</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HPV18&#x02009;+&#x02009;ve Invasive&#x02009;+&#x02009;HSIL</td><td align="center" valign="top" rowspan="1" colspan="1">1202</td><td align="center" valign="top" rowspan="1" colspan="1">113</td><td align="center" valign="top" rowspan="1" colspan="1">0.92 (0.39&#x02013;2.17)</td><td align="center" valign="top" rowspan="1" colspan="1">0.85</td><td align="center" valign="top" rowspan="1" colspan="1">906</td><td align="center" valign="top" rowspan="1" colspan="1">113</td><td align="center" valign="top" rowspan="1" colspan="1">1.25 (0.49&#x02013;3.17)</td><td align="center" valign="top" rowspan="1" colspan="1">0.642</td><td align="center" valign="top" rowspan="1" colspan="1">1064</td><td align="center" valign="top" rowspan="1" colspan="1">112</td><td align="center" valign="top" rowspan="1" colspan="1">1.09 (0.81&#x02013;1.49)</td><td align="center" valign="top" rowspan="1" colspan="1">0.561</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>HPV16/18&#x02009;+&#x02009;ve Overall</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">1202</td><td align="center" valign="top" rowspan="1" colspan="1">442</td><td align="center" valign="top" rowspan="1" colspan="1">0.86 (0.53&#x02013;1.41)</td><td align="center" valign="top" rowspan="1" colspan="1">0.549</td><td align="center" valign="top" rowspan="1" colspan="1">906</td><td align="center" valign="top" rowspan="1" colspan="1">438</td><td align="center" valign="top" rowspan="1" colspan="1">1.41 (0.82&#x02013;2.40)</td><td align="center" valign="top" rowspan="1" colspan="1">0.212</td><td align="center" valign="top" rowspan="1" colspan="1">1064</td><td align="center" valign="top" rowspan="1" colspan="1">418</td><td align="center" valign="top" rowspan="1" colspan="1">1.07 (0.89&#x02013;1.27)</td><td align="center" valign="top" rowspan="1" colspan="1">0.49</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HPV16/18&#x02009;+&#x02009;ve Invasive&#x02009;+&#x02009;HSIL</td><td align="center" valign="top" rowspan="1" colspan="1">1202</td><td align="center" valign="top" rowspan="1" colspan="1">415</td><td align="center" valign="top" rowspan="1" colspan="1">0.88 (0.53&#x02013;1.45)</td><td align="center" valign="top" rowspan="1" colspan="1">0.603</td><td align="center" valign="top" rowspan="1" colspan="1">906</td><td align="center" valign="top" rowspan="1" colspan="1">411</td><td align="center" valign="top" rowspan="1" colspan="1">1.43 (0.83&#x02013;2.46)</td><td align="center" valign="top" rowspan="1" colspan="1">0.197</td><td align="center" valign="top" rowspan="1" colspan="1">1064</td><td align="center" valign="top" rowspan="1" colspan="1">391</td><td align="center" valign="top" rowspan="1" colspan="1">1.10 (0.91&#x02013;1.31)</td><td align="center" valign="top" rowspan="1" colspan="1">0.329</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<bold>HPV (other)&#x02009;+&#x02009;ve overall</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">1202</td><td align="center" valign="top" rowspan="1" colspan="1">90</td><td align="center" valign="top" rowspan="1" colspan="1">0.57 (0.17&#x02013;1.84)</td><td align="center" valign="top" rowspan="1" colspan="1">0.343</td><td align="center" valign="top" rowspan="1" colspan="1">906</td><td align="center" valign="top" rowspan="1" colspan="1">91</td><td align="center" valign="top" rowspan="1" colspan="1">0.93 (0.29&#x02013;3.02)</td><td align="center" valign="top" rowspan="1" colspan="1">0.91</td><td align="center" valign="top" rowspan="1" colspan="1">1064</td><td align="center" valign="top" rowspan="1" colspan="1">89</td><td align="center" valign="top" rowspan="1" colspan="1">1.14 (0.82&#x02013;1.59)</td><td align="center" valign="top" rowspan="1" colspan="1">0.444</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HPV (other)&#x02009;+&#x02009;ve Invasive&#x02009;+&#x02009;HSIL</td><td align="center" valign="top" rowspan="1" colspan="1">1202</td><td align="center" valign="top" rowspan="1" colspan="1">68</td><td align="center" valign="top" rowspan="1" colspan="1">0.76 (0.23&#x02013;2.47)</td><td align="center" valign="top" rowspan="1" colspan="1">0.646</td><td align="center" valign="top" rowspan="1" colspan="1">906</td><td align="center" valign="top" rowspan="1" colspan="1">69</td><td align="center" valign="top" rowspan="1" colspan="1">1.23 (0.38&#x02013;3.95)</td><td align="center" valign="top" rowspan="1" colspan="1">0.733</td><td align="center" valign="top" rowspan="1" colspan="1">1064</td><td align="center" valign="top" rowspan="1" colspan="1">67</td><td align="center" valign="top" rowspan="1" colspan="1">0.96 (0.65&#x02013;1.43)</td><td align="center" valign="top" rowspan="1" colspan="1">0.841</td></tr></tbody></table><table-wrap-foot><fn id="jmv70195-tbl1-note-0001"><p>
<italic toggle="yes">Note:</italic> Cervical intraepithelial neoplasia was separated into LSIL/low&#x02010;grade (CIN1&#x02009;+&#x02009;CIN2&#x02009;&#x0003c;&#x02009;30 years) and HSIL/high&#x02010;grade (CIN2&#x02009;&#x02265;&#x02009;30 years&#x02009;+&#x02009;CIN3) subgroups.</p><p>Invasive cervical cancer was further divided into squamous epithelial cell carcinoma and adenocarcinoma. High&#x02010;risk dysplasia (CIN2&#x02009;&#x02265;&#x02009;30years&#x02009;+&#x02009;CIN3) and invasive cancer were also combined in joint analysis.</p><p>HSIL and invasive cancers were further stratified by HPV status (HPV 16, HPV18, HPV16/18 and other hrHPV).</p><p>All groups were compared against cancer&#x02010; and dysplasia&#x02010;free controls (with unknown serostatus). <italic toggle="yes">p</italic> values below 0.05 are marked in bold.</p></fn><fn id="jmv70195-tbl1-note-0002"><p>Abbreviations: CI, 95% confidence interval; OR, odds ratio for minor allele; <italic toggle="yes">p</italic>, <italic toggle="yes">p</italic> value from logistic regression analysis.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd.</copyright-holder></permissions></table-wrap><p>In logistic regression analyses, rs9272293 representing the GWS signal from our HPV16 and HPV16/18 GWASs at 6p21.32, was associated with overall cervical disease (OR&#x02009;=&#x02009;0.86, <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.004, 95% CI&#x02009;=&#x02009;0.78&#x02013;0.95) (Table&#x000a0;<xref rid="jmv70195-tbl-0001" ref-type="table">1</xref>). When stratified for disease severity, we found rs9272293 to be associated with invasive cervical cancer (OR&#x02009;=&#x02009;0.83, <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.002, 95% CI&#x02009;=&#x02009;0.74&#x02013;0.93), cervical adenocarcinoma (OR&#x02009;=&#x02009;0.78, <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.026, 95% CI&#x02009;=&#x02009;0.62&#x02013;0.97) and squamous cervical carcinoma (OR&#x02009;=&#x02009;0.87, <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.038, 95% CI&#x02009;=&#x02009;0.76&#x02013;0.99). The variant associated with HPV positive overall cervical disease (OR&#x02009;=&#x02009;0.83, <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.001, 95% CI&#x02009;=&#x02009;0.74&#x02013;0.93), and in stratified analysis, with HPV16+&#x02009;, HPV16/18+ overall disease and in a combined analysis of HPV16+ or HPV16/18&#x02009;+&#x02009;HSIL and invasive cancers (Table&#x000a0;<xref rid="jmv70195-tbl-0001" ref-type="table">1</xref>).</p><p>Among the sub&#x02010;genome&#x02010;wide significant candidates, four further variants showed evidence of association with overall cervical disease: rs742625 at 20p12.1 (HPV16+, HPV16/18+), rs79316639 at 2p25.2 (HPV18+), rs115851441 at 5p15.33 (HPV18+), and rs13288372 at 9q34.11 (HPV16/18+&#x02009;) (Table&#x000a0;<xref rid="jmv70195-tbl-0001" ref-type="table">1</xref> and Table&#x000a0;<xref rid="jmv70195-suppl-0011" ref-type="supplementary-material">S10</xref>). When analyses were restricted to invasive cervical cancer or specific histology groups, rs17867660 from the HPV16 seropositivity GWAS at 7q21.13 showed some evidence of association with overall invasive cancer (Table&#x000a0;<xref rid="jmv70195-tbl-0001" ref-type="table">1</xref>). Two other variants from the HPV16 seropositivity GWAS, rs11658042 at 17q12 and rs742625 at 20p12.1, as well as two variants from the HPV18 seropositivity GWAS, rs114272671 at 5q31.3 and rs12207703 at 6p24.1, showed evidence of association with squamous cervical carcinoma. One variant, rs72808738 from the HPV18 seropositivity GWAS at 5q31.3, was associated with adenocarcinoma of the cervix (Table&#x000a0;<xref rid="jmv70195-tbl-0001" ref-type="table">1</xref>).</p><p>In stratified analyses of dysplasia, rs79316639 and rs13288372 showed evidence of association with cervical dysplasia overall, high grade cervical dysplasia, and in combined analysis, with high grade cervical dysplasia and invasive cervical cancer (Table&#x000a0;<xref rid="jmv70195-tbl-0001" ref-type="table">1</xref>). By contrast, rs76710445 and rs115851441 (both from HPV18&#x02009;+&#x02009;GWAS) were also associated with low grade cervical dysplasias.</p><p>When stratified by HPV type (Table&#x000a0;<xref rid="jmv70195-tbl-0001" ref-type="table">1</xref>), rs114272671 was associated with HPV16+ cervical disease, and two variants rs6084436 and rs742625 were associated with HPV16/18+ cervical disease, whereas no variant was selectively associated with HPV18+ cervical disease in our analysis. However, sample numbers were the smallest for HPV18+ status. In the combined analysis of HPV16 and/or 18 positive high&#x02010;grade cervical dysplasia and invasive cervical cancer samples, we found further evidence of significant association with rs114272671 and rs742625.</p><p>Taken together, 12 out of the 25 candidate variants from the seropositivity GWAS showed some evidence of association with cervical cancer, either overall (5 variants) or only in subgroups (7 variants) (Table&#x000a0;<xref rid="jmv70195-tbl-0001" ref-type="table">1</xref>).</p></sec><sec id="jmv70195-sec-0120"><label>3.3</label><title>Bioinformatic Annotation</title><p>Up to 10 genes in close physical proximity to the top variants within 2Mbp (+/&#x02212; 1Mbp of the variant) were noted as putative candidate causal genes, as the levels of these genes may be influenced by the SNP genotype (Table&#x000a0;<xref rid="jmv70195-suppl-0005" ref-type="supplementary-material">S4A</xref>). The most significant variant, rs9272293, was reported to be a robust eQTL for multiple genes at the HLA region in whole blood in GTEx v8 (<italic toggle="yes">HLA&#x02010;DQB1</italic> with <italic toggle="yes">p</italic>&#x02009;=&#x02009;1.65&#x02009;&#x000d7;&#x02009;10E&#x02010;97 and <italic toggle="yes">HLA&#x02010;DQB2</italic>&#x000a0;with <italic toggle="yes">p</italic>&#x02009;=&#x02009;3.07&#x02009;&#x000d7;&#x02009;10E&#x02010;89, among others, Figure&#x000a0;<xref rid="jmv70195-suppl-0001" ref-type="supplementary-material">S3</xref>). Amongst our sub&#x02010;GWS variants that were genotyped, rs17867660 was found to be an eQTL in GTEx whole blood for <italic toggle="yes">GTPBP10</italic> at 7q21.13 (<italic toggle="yes">p</italic>&#x02009;=&#x02009;3.3&#x02009;&#x000d7;&#x02009;10E&#x02010;8, normalized effect size 0.13) and also in the eQTLGen consortium whole blood (<italic toggle="yes">p</italic>&#x02009;=&#x02009;1.73&#x02009;&#x000d7;&#x02009;10E&#x02010;44, <italic toggle="yes">z</italic>&#x02010;score&#x02009;=&#x02009;13.99) (Table&#x000a0;<xref rid="jmv70195-suppl-0005" ref-type="supplementary-material">S4A</xref>, Table&#x000a0;<xref rid="jmv70195-suppl-0006" ref-type="supplementary-material">S5</xref>). rs11658042 was an eQTL for <italic toggle="yes">SLFN5</italic> at 17q12 in GTEx whole blood (<italic toggle="yes">p</italic>&#x02009;=&#x02009;2.0&#x02009;&#x000d7;&#x02009;10E&#x02010;11, normalized effect size 0.23) and in the eQTLGen consortium for <italic toggle="yes">SLFN5, SLFN12L, SLFN13, SLFN11, RP11&#x02010;47L3.1, RP11&#x02010;799D4.4</italic>, and <italic toggle="yes">RP11&#x02010;1094M14.5</italic> (Figure&#x000a0;<xref rid="jmv70195-suppl-0001" ref-type="supplementary-material">S4</xref>, Table&#x000a0;<xref rid="jmv70195-suppl-0005" ref-type="supplementary-material">S4A</xref>, Table&#x000a0;<xref rid="jmv70195-suppl-0006" ref-type="supplementary-material">S5</xref>). The SNP rs12207703 was an eQTL for <italic toggle="yes">TBC1D7</italic> in whole blood in the eQTLGen consortium data (<italic toggle="yes">p</italic>&#x02009;=&#x02009;1.3&#x02009;&#x000d7;&#x02009;10E&#x02010;9, <italic toggle="yes">z</italic>&#x02010;score&#x02009;=&#x02009;6.07). None of the twelve significant variants were reported to be direct eQTLs in immune cell types accessed via DICE.</p><p>In bioinformatic analysis, we predicted allele&#x02010;specific transcription factor binding sites using HaploReg v4.2, RegulomeDB, and the PERFECTOS&#x02010;APE webtool for the 12 variants that showed evidence of association in at least one subgroup (scores provided in Table&#x000a0;<xref rid="jmv70195-suppl-0005" ref-type="supplementary-material">S4B</xref>, Table&#x000a0;<xref rid="jmv70195-suppl-0012" ref-type="supplementary-material">S11</xref>, Table&#x000a0;<xref rid="jmv70195-suppl-0013" ref-type="supplementary-material">S12</xref>, Table&#x000a0;<xref rid="jmv70195-suppl-0014" ref-type="supplementary-material">S13</xref>). We also submitted the top 12 variants to FORGEdb for annotation, however, the results were largely similar to individual annotations via HaploReg v4.2, GTEx, eQTLGen and RegulomeDB (Table&#x000a0;<xref rid="jmv70195-suppl-0015" ref-type="supplementary-material">S14</xref>). The chromatin status in HeLa cells was quiescent or weakly repressed polycomb for 11 out of 12 submitted variants according to the Regulome database, except for rs13288372, which appears to be in an enhancer element (Table&#x000a0;<xref rid="jmv70195-suppl-0005" ref-type="supplementary-material">S4A</xref>). The annotations for all linked variants at <italic toggle="yes">R</italic>
<sup>2</sup>&#x02009;&#x02265;&#x02009;0.8 were also generated using HaploReg v4.2 and RegulomeDB (Table&#x000a0;<xref rid="jmv70195-suppl-0012" ref-type="supplementary-material">S11</xref>, Table&#x000a0;<xref rid="jmv70195-suppl-0013" ref-type="supplementary-material">S12</xref>).</p></sec><sec id="jmv70195-sec-0130"><label>3.4</label><title>Gene Expression Analysis</title><p>We performed eQTL analysis in our series of cervical tissue scrapes (<italic toggle="yes">n</italic>&#x02009;=&#x02009;280) to investigate how the genotype of the most significant variant rs9272293 at 6p21.32 can affect the expression of the neighboring genes at this locus. We found rs9272293 to be an eQTL for multiple genes among all samples tested: <italic toggle="yes">HLA&#x02010;DRB1</italic>, <italic toggle="yes">HLA&#x02010;DQB1&#x02010;AS1</italic>, <italic toggle="yes">C4B</italic>, <italic toggle="yes">HLA&#x02010;DRB5</italic>, <italic toggle="yes">HLA&#x02010;DRB6</italic>, <italic toggle="yes">HLA&#x02010;DQB1</italic>, and <italic toggle="yes">HLA&#x02010;DPB2</italic> (Figure&#x000a0;<xref rid="jmv70195-fig-0002" ref-type="fig">2</xref>). Transcript levels of <italic toggle="yes">HLA&#x02010;DRB1</italic> (<italic toggle="yes">P</italic>
<sub>Trend</sub>&#x02009;&#x0003c;&#x02009;0.001), <italic toggle="yes">HLA&#x02010;DQB1&#x02010;AS1</italic> (<italic toggle="yes">P</italic>
<sub>Trend</sub>&#x02009;&#x0003c;&#x02009;0.001), <italic toggle="yes">HLA&#x02010;DRB5</italic> (<italic toggle="yes">P</italic>
<sub>Trend</sub>&#x02009;&#x0003c;&#x02009;0.001), <italic toggle="yes">HLA&#x02010;DRB6</italic> (<italic toggle="yes">P</italic>
<sub>Trend</sub>&#x02009;=&#x02009;0.01), and <italic toggle="yes">HLA&#x02010;DQB1</italic> (<italic toggle="yes">P</italic>
<sub>Trend</sub>&#x02009;=&#x02009;0.02) were increased in the presence of the rare allele A that was protective in our association analyses (Figure&#x000a0;<xref rid="jmv70195-fig-0002" ref-type="fig">2</xref>). Transcript levels of <italic toggle="yes">C4B</italic> (<italic toggle="yes">P</italic>
<sub>Trend</sub>&#x02009;=&#x02009;0.05) and <italic toggle="yes">HLA&#x02010;DPB2</italic> (<italic toggle="yes">P</italic>
<sub>Trend</sub>&#x02009;=&#x02009;0.03) appeared decreased with the rare homozygous genotype (Figure&#x000a0;<xref rid="jmv70195-fig-0002" ref-type="fig">2</xref>). The eQTL effects for rs9272293 with <italic toggle="yes">HLA&#x02010;DQB1&#x02010;AS1</italic>, <italic toggle="yes">HLA&#x02010;DRB5</italic>, <italic toggle="yes">HLA&#x02010;DRB6</italic>, and <italic toggle="yes">HLA&#x02010;DQB1</italic> were mainly observed in HPV negative (noncancerous/dysplastic) samples (<italic toggle="yes">HLA&#x02010;DQB1&#x02010;AS1</italic>: <italic toggle="yes">P</italic>
<sub>Trend</sub>&#x02009;&#x0003c;&#x02009;0.001, <italic toggle="yes">HLA&#x02010;DRB5</italic>: <italic toggle="yes">P</italic>
<sub>Trend</sub>&#x02009;&#x0003c;&#x02009;0.001, <italic toggle="yes">HLA&#x02010;DRB6</italic>: <italic toggle="yes">P</italic>
<sub>Trend</sub>&#x02009;=&#x02009;0.04, and <italic toggle="yes">HLA&#x02010;DQB1</italic>: <italic toggle="yes">P</italic>
<sub>Trend</sub>&#x02009;=&#x02009;0.03, <italic toggle="yes">HSPA1L</italic>: <italic toggle="yes">P</italic>
<sub>Trend</sub>&#x02009;=&#x02009;0.04 (Figure&#x000a0;<xref rid="jmv70195-fig-0003" ref-type="fig">3</xref>), whereas rs9272293 remained an eQTL for <italic toggle="yes">HLA&#x02010;DRB1</italic> in both HPV positive (<italic toggle="yes">P</italic>
<sub>Trend</sub>&#x02009;&#x0003c;&#x02009;0.001) and HPV negative samples (<italic toggle="yes">P</italic>
<sub>Trend</sub>&#x02009;=&#x02009;0.001).</p><fig position="float" fig-type="Figure" id="jmv70195-fig-0002"><label>Figure 2</label><caption><p>eQTL analysis for rs9272293 in all cervical tissues. &#x02212;log10 relative quantities (+/&#x02212;SEM) are shown on the <italic toggle="yes">y</italic> axis, together with genotypes on the <italic toggle="yes">x</italic> axis (A1&#x02009;=&#x02009;common homozygous genotype GG, het.&#x02009;=&#x02009;heterozygous genotype GA, A2&#x02009;=&#x02009;rare homozygous genotype AA). Sample numbers per group are written below the respective bars on the <italic toggle="yes">x</italic> axis. <italic toggle="yes">p</italic> values are indicated after ANOVA was performed between three groups followed by a linear trend test, with the common genotype as the control.</p></caption><graphic xlink:href="JMV-97-e70195-g002" position="anchor" id="jats-graphic-3"/></fig><fig position="float" fig-type="Figure" id="jmv70195-fig-0003"><label>Figure 3</label><caption><p>eQTL analysis for rs9272293 in HPV negative and HPV positive cervical tissues. &#x02212;log10 relative quantities (+/&#x02212; SEM) are shown on the <italic toggle="yes">y</italic> axis, together with genotypes on the <italic toggle="yes">x</italic> axis (A1&#x02009;=&#x02009;common homozygous genotype GG, het.&#x02009;=&#x02009;heterozygous genotype GA, A2&#x02009;=&#x02009;rare homozygous genotype AA). Sample numbers per group are written below the respective bars on the <italic toggle="yes">x</italic> axis. <italic toggle="yes">p</italic> values are indicated after ANOVA was performed between three groups followed by a linear trend test, with the common genotype as the control.</p></caption><graphic xlink:href="JMV-97-e70195-g003" position="anchor" id="jats-graphic-5"/></fig><p>For the eight eQTL genes of rs9272293, a pairwise gene&#x02010;gene correlation analysis was performed to examine the influence of genotype on coordinated gene expression. We found evidence for a differential correlation between some of these genes under the three genotypes of rs9272293, for example, for the pair <italic toggle="yes">HLA&#x02010;DPB2</italic>/<italic toggle="yes">HLA&#x02010;DRB5</italic> (Figure&#x000a0;<xref rid="jmv70195-fig-0004" ref-type="fig">4</xref>). For gene transcripts that were very low expressed, Pearson correlation analysis revealed that rs9272293 genotype may additionally associate with the detection of further genes (CT&#x02009;&#x02264;&#x02009;32) beyond the eQTL genes mentioned above (Table&#x000a0;<xref rid="jmv70195-suppl-0008" ref-type="supplementary-material">S7</xref>).</p><fig position="float" fig-type="Figure" id="jmv70195-fig-0004"><label>Figure 4</label><caption><p>Correlation analysis for genes that are eQTLs for rs9272293. Pearson correlation R values are shown between genes that showed evidence to be eQTLs for rs9272293. Panels from left to right indicate the genotype of rs9272293 (A1&#x02009;=&#x02009;common homozygous genotype GG, het. = heterozygous genotype GA, A2&#x02009;=&#x02009;rare homozygous genotype AA). Negative correlation (<italic toggle="yes">R</italic>&#x02009;=&#x02009;&#x02212;1) is shown in deep red color, whereas positive correlation (<italic toggle="yes">R</italic>&#x02009;=&#x02009;1) is shown in deep blue color. Missing values are represented with a black X through the white box.</p></caption><graphic xlink:href="JMV-97-e70195-g001" position="anchor" id="jats-graphic-7"/></fig></sec></sec><sec sec-type="discussion" id="jmv70195-sec-0140"><label>4</label><title>Discussion</title><p>Genome&#x02010;wide association studies for cervical cancer have identified multiple susceptibility variants on four chromosomal regions, most of them arising at the HLA locus [<xref rid="jmv70195-bib-0006" ref-type="bibr">6</xref>, <xref rid="jmv70195-bib-0007" ref-type="bibr">7</xref>, <xref rid="jmv70195-bib-0008" ref-type="bibr">8</xref>, <xref rid="jmv70195-bib-0009" ref-type="bibr">9</xref>, <xref rid="jmv70195-bib-0010" ref-type="bibr">10</xref>, <xref rid="jmv70195-bib-0011" ref-type="bibr">11</xref>, <xref rid="jmv70195-bib-0012" ref-type="bibr">12</xref>]. A persistent infection with high risk HPV types is found in almost all cervical cancers [<xref rid="jmv70195-bib-0004" ref-type="bibr">4</xref>]. Given this prominent role of HPV infection and the evidence for HLA&#x02010;mediated cervical cancer risk, HPV seropositivity GWASs can provide insight into further HPV type specific genetic risk factors for cervical cancer [<xref rid="jmv70195-bib-0015" ref-type="bibr">15</xref>, <xref rid="jmv70195-bib-0016" ref-type="bibr">16</xref>, <xref rid="jmv70195-bib-0028" ref-type="bibr">28</xref>].</p><p>In this study, we aimed to test variants from HPV seropositivity GWASs for their role in cervical cancer risk. Out of 25 candidates, twelve independent signals showed evidence of association in our case&#x02010;control cohort for cervical cancer and dysplasia in at least one of the subgroups, with five of them being associated with overall cervical disease. Variant rs9272293 at 6p21.32 was the lead variant from the GWAS for both HPV16 as well as HPV16/18 serostatus and had the highest PIP in a credible set in fine&#x02010;mapping analysis using SuSiE and Rsparsepro. rs9272293 associated mainly with HPV16&#x02010;positive cancers, consistent with the initial seropositivity GWAS since the association for the signal represented by rs9272293 was largely driven by HPV16 while HPV18 seropositive GWAS alone did not identify significant associations at 6p21.32&#x02010;33 (HLA region) at GWS. This variant is not linked with previously reported CC GWAS susceptibility loci in this region [<xref rid="jmv70195-bib-0006" ref-type="bibr">6</xref>] and thus represents an independent novel signal. We additionally found eQTL evidence for this SNP, with the rare protective allele associating with increased transcript levels of <italic toggle="yes">HLA&#x02010;DQB1, HLA&#x02010;DQB1&#x02010;AS1</italic>, <italic toggle="yes">HLA&#x02010;DRB1</italic>, <italic toggle="yes">HLA&#x02010;DRB5</italic> and <italic toggle="yes">HLA&#x02010;DRB6</italic> in cervical epithelial cells. As some of these eQTL effects disappeared in HPV positive tissue samples, HPV infection may counteract the protective effect of the rare allele. It is possible that rs9272293 modifies immune response through regulation of MHC class II genes. Variants at <italic toggle="yes">HLA&#x02010;DQB1</italic> have previously been associated with an increased risk of cervical disease [<xref rid="jmv70195-bib-0029" ref-type="bibr">29</xref>, <xref rid="jmv70195-bib-0030" ref-type="bibr">30</xref>, <xref rid="jmv70195-bib-0031" ref-type="bibr">31</xref>] and increased <italic toggle="yes">HLA&#x02010;DQB1</italic> may act as a biomarker for cervical cancer, with its expression being associated with an increased immune response to cervical tumors [<xref rid="jmv70195-bib-0032" ref-type="bibr">32</xref>]. The novel lncRNA <italic toggle="yes">HLA&#x02010;DQB1&#x02010;AS1</italic> was shown to be associated with a GWAS SNP (rs2647046) for Hepatitis&#x02010;B associated hepatocellular carcinoma, and has been nominated as a potential oncogene [<xref rid="jmv70195-bib-0033" ref-type="bibr">33</xref>, <xref rid="jmv70195-bib-0034" ref-type="bibr">34</xref>], however, no association with cervical cancer has been reported thus far. Expression of <italic toggle="yes">HLA&#x02010;DRB</italic> genes also have been associated with cervical cancer risk [<xref rid="jmv70195-bib-0035" ref-type="bibr">35</xref>, <xref rid="jmv70195-bib-0036" ref-type="bibr">36</xref>, <xref rid="jmv70195-bib-0037" ref-type="bibr">37</xref>], and induction of these gene products may contribute to exogenous antigen presentation on cervical epithelial cells and activation of T&#x02010;helper cells. On the other hand, the protective rare allele of rs9272293 also may be associated with decreased levels of <italic toggle="yes">C4B</italic> and <italic toggle="yes">HLA&#x02010;DPB2</italic>. A previous study showed increased levels of <italic toggle="yes">C4B</italic> in cervical carcinoma patients [<xref rid="jmv70195-bib-0038" ref-type="bibr">38</xref>] and higher <italic toggle="yes">C4B</italic> levels were associated with decreased survival in the TCGA cervical cancer dataset (<ext-link xlink:href="https://www.proteinatlas.org/ENSG00000224389-C4B/pathology/cervical%2Bcancer/CESC" ext-link-type="uri">https://www.proteinatlas.org/ENSG00000224389-C4B/pathology/cervical+cancer/CESC</ext-link>). Other independent risk variants for CC susceptibility have been reported at <italic toggle="yes">HLA&#x02010;DPB2</italic> previously [<xref rid="jmv70195-bib-0039" ref-type="bibr">39</xref>, <xref rid="jmv70195-bib-0040" ref-type="bibr">40</xref>] but no clear role of this gene in cervical pathogenesis has been reported to date.</p><p>Another HPV16 seropositivity variant that was genome&#x02010;wide significant in the initial GWAS, rs991757, did not associate with cervical cancer in the subsequent screening. It is possible that not all of the variants that mediate HPV infection are equally relevant for immune escape and carcinogenesis. Alternatively, our study power was not sufficient to detect a disease&#x02010;causing effect, or it could have been a false positive. However, we identified potential associations with cervical cancer for 11 out of 23 additional candidate variants that had been sub&#x02010;genome&#x02010;wide significant in the initial seropositivity GWAS, with four of them being associated with overall cervical disease and seven with cervical disease subgroups. Among the four variants associated with overall cervical cancer, rs742625 had arisen from the HPV16&#x02010;seropositivity GWAS, rs115851441 and rs79316639 from the HPV18&#x02010;seropositivity GWAS, and rs13288372 came from the combined HPV16/HPV18 seropositivity GWAS.</p><p>Since we did not functionally test the effects of these variants or test them to be eQTLs in our cervical epithelial cohort, we can only speculate on the possible nearest candidate genes that can underlie these signals. rs742625 is located upstream of <italic toggle="yes">SNX5</italic> and <italic toggle="yes">SNORD17</italic>. <italic toggle="yes">SNX5</italic> encodes sorting nexin 5, an endosomal protein involved in viral replication and entry and virus&#x02010;induced autophagy [<xref rid="jmv70195-bib-0041" ref-type="bibr">41</xref>] and may play an oncogenic role in SCC of head and neck [<xref rid="jmv70195-bib-0042" ref-type="bibr">42</xref>] by modulating the degradation of oncogenic proteins such as c&#x02010;Myc and Cyclin&#x02010;E1 whereas <italic toggle="yes">SNORD17</italic> encodes a small nucleolar RNA that is reported to inactivate p53 and enhance disease progression in hepatocellular carcinoma [<xref rid="jmv70195-bib-0043" ref-type="bibr">43</xref>], another virally&#x02010;induced cancer.</p><p>rs115851441 on 5p15.33 is located close to <italic toggle="yes">hsa&#x02010;miR&#x02010;4277</italic> and <italic toggle="yes">lnc&#x02010;NDUFS6&#x02010;3</italic> (361&#x02009;bp 5&#x02032; of <italic toggle="yes">CTD&#x02010;2587M23.1)</italic>. This signal is distant and not correlated with previously reported CC susceptibility variants at <italic toggle="yes">CLPTM1L</italic> [<xref rid="jmv70195-bib-0011" ref-type="bibr">11</xref>] or an oropharyngeal cancer susceptibility variant (rs10462706) [<xref rid="jmv70195-bib-0044" ref-type="bibr">44</xref>] on 5p15.33. rs79316639 at 2p25.2 is located next to the <italic toggle="yes">SRY&#x02010;related HMG&#x02010;box gene 11</italic> (<italic toggle="yes">SOX11</italic>) gene. <italic toggle="yes">SOX11</italic> is a transcription factor whose expression is associated with HPV status and is downregulated in high&#x02010;grade cervical dysplasia and cervical cancer via hypermethylation of its promotor region [<xref rid="jmv70195-bib-0045" ref-type="bibr">45</xref>]. rs13288372 is located at <italic toggle="yes">Neuronal Calcium Sensor 1</italic> (<italic toggle="yes">NCS1</italic>) (9q34.11) that encodes a regulator of calcium&#x02010;dependent, G protein&#x02010;coupled receptor phosphorylation in neurons. <italic toggle="yes">NCS1</italic> overexpression promotes migration and invasion in breast cancer [<xref rid="jmv70195-bib-0046" ref-type="bibr">46</xref>], and <italic toggle="yes">NCS1</italic> is an unfavorable prognostic marker in kidney, breast and endometrial cancer (<ext-link xlink:href="https://www.proteinatlas.org/ENSG00000107130-NCS1" ext-link-type="uri">https://www.proteinatlas.org/ENSG00000107130-NCS1</ext-link>).</p><p>Among those variants potentially associated with cervical cancer subgroups, the minor allele of rs11658042 at 17q12 was found to be associated with a decreased risk of squamous carcinoma in our cohort. This variant is a reported eQTL for <italic toggle="yes">SLFN5</italic> in whole blood in GTEx v8, with the rare allele increasing levels of <italic toggle="yes">SLFN5</italic>. <italic toggle="yes">SLFN5</italic> encodes Schlafen 5, a p53 target protein, whose role as an antiviral restriction factor in suppressing viral transcription of herpes simplex virus [<xref rid="jmv70195-bib-0047" ref-type="bibr">47</xref>] and human immunodeficiency virus (HIV) has been reported previously [<xref rid="jmv70195-bib-0048" ref-type="bibr">48</xref>]. The levels of <italic toggle="yes">SLFN5</italic> were shown to be lower in human papillomavirus E5 positive murine dendritic D2.4 cells, indicating a viral response to decrease protective protein levels [<xref rid="jmv70195-bib-0049" ref-type="bibr">49</xref>]. <italic toggle="yes">SLFN5</italic> is also reported to play a role in epithelial&#x02010;mesenchymal transformation in breast cancer [<xref rid="jmv70195-bib-0050" ref-type="bibr">50</xref>], among others [<xref rid="jmv70195-bib-0051" ref-type="bibr">51</xref>]. This signal is independent of the previously known CC&#x02010;associated GWAS signal on 17q12 (rs8067378, at <italic toggle="yes">GSDMB</italic>) [<xref rid="jmv70195-bib-0008" ref-type="bibr">8</xref>].</p><p>We investigated whether some of the variants identified here would replicate in other published case&#x02010;control datasets for cervical cancer. The lead GWAS variant rs9272293 (HPV16 +,HPV16/18&#x02009;+&#x02009;) associated with cervical cancer in both the FinnGen R8 (<italic toggle="yes">p</italic>&#x02009;=&#x02009;7.2&#x02009;&#x000d7;&#x02009;10E&#x02010;4) and KoGES PheWeb (<italic toggle="yes">p</italic>&#x02009;=&#x02009;2.3&#x02009;&#x000d7;&#x02009;10E&#x02010;2) biobanks, and the linked lead SNP rs17612669 had supportive evidence for association in the Japanese Biobank (<italic toggle="yes">p</italic>&#x02009;=&#x02009;4.50&#x02009;&#x000d7;&#x02009;10E&#x02010;2). There was also supportive evidence for some variants below genome&#x02010;wide significance, such as rs11658042 (17q12, FinnGen R8 <italic toggle="yes">p</italic>&#x02009;=&#x02009;3.3&#x02009;&#x000d7;&#x02009;10E&#x02010;3), rs17867660 (7q21.13, FinnGen R8 <italic toggle="yes">p</italic>&#x02009;=&#x02009;3.3&#x02009;&#x000d7;&#x02009;10E&#x02010;2), rs79316639 (2p25.2, UK Biobank <italic toggle="yes">p</italic>&#x02009;=&#x02009;1.2&#x02009;&#x000d7;&#x02009;10E&#x02010;3) and rs742625 (20p12.1, KOGES PheWeb <italic toggle="yes">p</italic>&#x02009;=&#x02009;1.6&#x02009;&#x000d7;&#x02009;10E&#x02010;2), to be associated with cervical cancer in available GWAS summary statistics from national biobanks, though these biobank data did not allow for stratification by HPV status.</p><p>Our study shows that genetic determinants of seropositivity can be relevant in understanding genetic risk in the case of virus&#x02010;driven cancers. Cervical cancer is not the only HPV&#x02010;driven cancer, and HPV seropositivity variants may be interesting for determining the risk for head and neck cancers and anogenital cancers as well. The first GWAS for HPV seropositivity [<xref rid="jmv70195-bib-0014" ref-type="bibr">14</xref>] also reported on replication genotyping in a Latin&#x02010;American cohort of head and neck cancer and found supportive evidence for the lead SNP. We further investigated whether the variants arising from the current study are relevant in other published data sets of likely HPV&#x02010;associated cancers. rs9272293 associated with vulva cancer (<italic toggle="yes">p</italic>&#x02009;=&#x02009;1.2&#x02009;&#x000d7;&#x02009;10E&#x02010;4, <italic toggle="yes">&#x000df;&#x02009;</italic>=&#x02009;0.35) and anal cancer (<italic toggle="yes">p</italic>&#x02009;=&#x02009;6.6&#x02009;&#x000d7;&#x02009;10E&#x02010;4, <italic toggle="yes">&#x000df;&#x02009;</italic>=&#x02009;0.46) in FinnGen R8, rs17612669 associated with lung cancer (<italic toggle="yes">p</italic>&#x02009;=&#x02009;2.5&#x02009;&#x000d7;&#x02009;10E&#x02010;7) in a meta&#x02010;analysis of the KOGES and biobank Japan, rs11658042 and rs17867660 associated with oropharyngeal cancer (<italic toggle="yes">p</italic>&#x02009;=&#x02009;6.03&#x02009;&#x000d7;&#x02009;10E&#x02010;3, <italic toggle="yes">&#x000df;&#x02009;</italic>=&#x02009;0.38; <italic toggle="yes">p</italic>&#x02009;=&#x02009;4.3&#x02009;&#x000d7;&#x02009;10E&#x02010;2, <italic toggle="yes">&#x000df;</italic>&#x02009;=&#x02009;&#x02212;0.15) in the UK biobank, rs79316639 associated with rectal cancer (<italic toggle="yes">p</italic>&#x02009;=&#x02009;1.1&#x02009;&#x000d7;&#x02009;10E&#x02010;2, <italic toggle="yes">&#x000df;&#x02009;</italic>=&#x02009;0.41) in FinnGen R8 and rs742625 associated with laryngeal cancer (<italic toggle="yes">p</italic>&#x02009;=&#x02009;8.9&#x02009;&#x000d7;&#x02009;10E&#x02010;3, <italic toggle="yes">&#x000df;&#x02009;</italic>=&#x02009;0.71) in the UK biobank. These observations invite follow&#x02010;up investigations for validation in larger cohorts or meta&#x02010;analyses with further HPV seropositivity summary statistics, and functional analysis of the proposed risk variants.</p><p>Although our findings cast light on the importance of the germline interaction between HPV and cervical cancer, this study has limitations. Our initial selection of HPV associated variants was based on serostatus, not seroreactivity. This was due to sample size limitations in the original UK Biobank GWAS, yet could induce bias in the genetic associations due to behavioral differences (and not genetic alterations) driving HPV status. We also note that our sample size for HPV18&#x02010;seropositive individuals was far smaller than for HPV16, and it contained a substantial portion of HPV16/HPV18 double positives. Our association results were thus largely driven by HPV16 seropositivity. While the different design of the HPV18 seropositivity GWAS (including HPV16/HPV18 double positives in the cases and HPV16+/HPV18&#x02212; as well as HPV16&#x02010;/HPV18&#x02212; in the controls) was for the purposes of statistical power, the lack of signals identified at chromosome 6 as compared to the HPV any seropositivity GWAS (HPV16+ and/or HPV18+ vs. no HPV detected) would indicate that the inclusion of HPV16+/HPV18&#x02212; samples in the controls of the former GWAS diluted the effects. However, this would not mean that signals arising in the HPV16 and the HPV any GWAS analyses are irrelevant for HPV18 seropositivity. Larger sample sizes with HPV18 only seropositivity may help overcome this limitation of our current study.</p><p>Although we confirmed a nominally significant association with cancer risk for many of the HPV seropositivity GWAS signals, others were not associated with cancer. This could be due to the relatively small case&#x02010;control series combined with small effect sizes, or due to the lack of a true association. We tested only common variants in this study. Additionally, the genotyped variants may not underlie the association and may act as proxies for the true causal variants that remain to be determined in fine&#x02010;mapping studies. At present there are no available resources for such fine&#x02010;mapping or eQTL colocalization studies in the cervix, that might provide stronger evidence to identify causal risk loci. Our genetic study was limited to participants of European ancestry and this invites validation studies in larger, diverse cohorts in the future.</p><p>Identifying genetic risk variants that act as modulators of this infection&#x02010;induced cancer may bring us closer to understanding the molecular mechanisms underlying invasive cervical disease and eventually lead to new strategies in prevention and treatment. Chronic HPV infection is a known risk factor for cervical cancer, and the genetic susceptibility underlying an HPV infection can help inform risk for cervical cancer, as well as for other HPV&#x02010;associated cancers. Such variants mediating infection and cancer risk may have pleiotropic effects and are worthy of further investigation.</p></sec><sec sec-type="conclusions" id="jmv70195-sec-0150"><label>5</label><title>Conclusion</title><p>Our study corroborates the notion that the shared genetic risk between HPV seropositivity and invasive cervical disease can guide the identification of novel cervical cancer susceptibility loci. Larger GWASs on HPV seropositivity and seroreactivity as well as longitudinal studies on persistent HPV infection risk will be helpful in delineating the genetic risk factors underlying cervical cancer, as well as other HPV&#x02010;induced cancers.</p></sec><sec id="jmv70195-sec-0160"><title>Author Contributions</title><p>
<bold>Theresa Beckhaus:</bold> formal analysis, investigation, writing&#x02013;original draft. <bold>Linda Kachuri, Taishi Connor Nakase, Peter Sch&#x000fc;rmann, Rieke Eisenbl&#x000e4;tter, Maya Geerts, Tracy A O'Mara,</bold> and <bold>Stephan Francis:</bold> formal analysis, investigation, writing&#x02013;review and editing. <bold>Gerd B&#x000f6;hmer, Hans&#x02010;Georg Strau&#x003b2;, Christine Hirchenhain, Monika Schmidmayr, Florian M&#x000fc;ller, Peter A.&#x000a0;Fasching, Alexander Luyten, Norman H&#x000e4;fner, Matthias Jentschke,</bold> and <bold>Peter Hillemanns:</bold> resources, data curation, writing&#x02013;review and editing. <bold>John S. Witte:</bold> resources, supervision, writing&#x02013;review and editing. <bold>Thilo D&#x000f6;rk:</bold> data curation, funding acquisition, resources, supervision, writing&#x02013;original draft. <bold>Dhanya Ramachandran:</bold> formal analysis, investigation, funding acquisition, resources, supervision, visualization, writing&#x02013;original draft.</p></sec><sec id="jmv70195-sec-0180"><title>Ethics Statement</title><p>The Ethics committee of Hannover Medical School approved this study (votes 441 and 10737).</p></sec><sec id="jmv70195-sec-0190"><title>Consent</title><p>Written and informed consent was collected from each patient that participated in this study. GWAS analyses were conducted with approved access to UK Biobank data under application numbers 14105 and 25331.</p></sec><sec sec-type="COI-statement" id="jmv70195-sec-0200"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="jmv70195-suppl-0001" position="float" content-type="local-data"><caption><p>Supporting information.</p></caption><media xlink:href="JMV-97-e70195-s011.pdf"/></supplementary-material><supplementary-material id="jmv70195-suppl-0002" position="float" content-type="local-data"><caption><p>Supporting information.</p></caption><media xlink:href="JMV-97-e70195-s010.xlsx"/></supplementary-material><supplementary-material id="jmv70195-suppl-0003" position="float" content-type="local-data"><caption><p>Supporting information.</p></caption><media xlink:href="JMV-97-e70195-s002.xlsx"/></supplementary-material><supplementary-material id="jmv70195-suppl-0004" position="float" content-type="local-data"><caption><p>Supporting information.</p></caption><media xlink:href="JMV-97-e70195-s014.xlsx"/></supplementary-material><supplementary-material id="jmv70195-suppl-0005" position="float" content-type="local-data"><caption><p>Supporting information.</p></caption><media xlink:href="JMV-97-e70195-s012.xlsx"/></supplementary-material><supplementary-material id="jmv70195-suppl-0006" position="float" content-type="local-data"><caption><p>Supporting information.</p></caption><media xlink:href="JMV-97-e70195-s015.xlsx"/></supplementary-material><supplementary-material id="jmv70195-suppl-0007" position="float" content-type="local-data"><caption><p>Supporting information.</p></caption><media xlink:href="JMV-97-e70195-s009.xlsx"/></supplementary-material><supplementary-material id="jmv70195-suppl-0008" position="float" content-type="local-data"><caption><p>Supporting information.</p></caption><media xlink:href="JMV-97-e70195-s006.xlsx"/></supplementary-material><supplementary-material id="jmv70195-suppl-0009" position="float" content-type="local-data"><caption><p>Supporting information.</p></caption><media xlink:href="JMV-97-e70195-s008.xlsx"/></supplementary-material><supplementary-material id="jmv70195-suppl-0010" position="float" content-type="local-data"><caption><p>Supporting information.</p></caption><media xlink:href="JMV-97-e70195-s003.xlsx"/></supplementary-material><supplementary-material id="jmv70195-suppl-0011" position="float" content-type="local-data"><caption><p>Supporting information.</p></caption><media xlink:href="JMV-97-e70195-s007.xlsx"/></supplementary-material><supplementary-material id="jmv70195-suppl-0012" position="float" content-type="local-data"><caption><p>Supporting information.</p></caption><media xlink:href="JMV-97-e70195-s013.xlsx"/></supplementary-material><supplementary-material id="jmv70195-suppl-0013" position="float" content-type="local-data"><caption><p>Supporting information.</p></caption><media xlink:href="JMV-97-e70195-s001.xlsx"/></supplementary-material><supplementary-material id="jmv70195-suppl-0014" position="float" content-type="local-data"><caption><p>Supporting information.</p></caption><media xlink:href="JMV-97-e70195-s016.xlsx"/></supplementary-material><supplementary-material id="jmv70195-suppl-0015" position="float" content-type="local-data"><caption><p>Supporting information.</p></caption><media xlink:href="JMV-97-e70195-s004.xlsx"/></supplementary-material><supplementary-material id="jmv70195-suppl-0016" position="float" content-type="local-data"><caption><p>Supporting information.</p></caption><media xlink:href="JMV-97-e70195-s005.docx"/></supplementary-material></sec></body><back><ack id="jmv70195-sec-0170"><title>Acknowledgments</title><p>The authors thank Fabienne H&#x000fc;lse and Patricia Hanel for their technical assistance. D.R. and T.D. received funding from the H.W. &#x00026; J. Hector Stiftung (M2414). D.R. received funding from the Tumorstiftung at Hannover Medical School. M.G. received a stipend from the University of British Columbia. The Cervigen consortium was established with funding from the Bruno and Helene J&#x000f6;ster Foundation. Open Access funding enabled and organized by Projekt DEAL.</p></ack><sec sec-type="data-availability" id="jmv70195-sec-0220"><title>Data Availability Statement</title><p>The data that support the findings of this study are available from the corresponding authors upon request.</p></sec><ref-list content-type="cited-references" id="jmv70195-bibl-0001"><title>References</title><ref id="jmv70195-bib-0001"><label>1</label><mixed-citation publication-type="miscellaneous" id="jmv70195-cit-0001">
<string-name>
<given-names>L.</given-names>
<surname>Bruni</surname>
</string-name>, <string-name>
<given-names>G.</given-names>
<surname>Albero</surname>
</string-name>, <string-name>
<given-names>B.</given-names>
<surname>Serrano</surname>
</string-name>, et al., Human Papillomavirus and Related Diseases in the World. ICO/IARC Information Centre on HPV and Cancer. (HPV Inf Centre) [Internet] <year>2023</year>; <ext-link xlink:href="http://www.hpvcentre.net" ext-link-type="uri">www.hpvcentre.net</ext-link>.</mixed-citation></ref><ref id="jmv70195-bib-0002"><label>2</label><mixed-citation publication-type="miscellaneous" id="jmv70195-cit-0002">
<string-name>
<given-names>L.</given-names>
<surname>Bruni</surname>
</string-name>, <string-name>
<given-names>G.</given-names>
<surname>Albero</surname>
</string-name>, <string-name>
<given-names>B.</given-names>
<surname>Serrano</surname>
</string-name>, et al., <year>2021</year>Bosch FX de SSIIC on H and C (HPV IC. Human Papillomavirus and Related Diseases in Germany. Summary Report 22 October 2021. [12092022]. <ext-link xlink:href="https://www.hpvcentre.com" ext-link-type="uri">https://www.hpvcentre.com</ext-link>.</mixed-citation></ref><ref id="jmv70195-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="jmv70195-cit-0003">
<string-name>
<given-names>E. M.</given-names>
<surname>Burd</surname>
</string-name>, &#x0201c;<article-title>Human Papillomavirus and Cervical Cancer</article-title>,&#x0201d; <source>Clinical Microbiology Reviews</source>
<volume>16</volume> (<year>2003</year>): <fpage>1</fpage>&#x02013;<lpage>17</lpage>.<pub-id pub-id-type="pmid">12525422</pub-id>
</mixed-citation></ref><ref id="jmv70195-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="jmv70195-cit-0004">
<string-name>
<given-names>E. J.</given-names>
<surname>Crosbie</surname>
</string-name>, <string-name>
<given-names>M. H.</given-names>
<surname>Einstein</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Franceschi</surname>
</string-name>, and <string-name>
<given-names>H. C.</given-names>
<surname>Kitchener</surname>
</string-name>, &#x0201c;<article-title>Human Papillomavirus and Cervical Cancer</article-title>,&#x0201d; <source>Lancet</source>
<volume>382</volume> (<year>2013</year>): <fpage>889</fpage>&#x02013;<lpage>899</lpage>.<pub-id pub-id-type="pmid">23618600</pub-id>
</mixed-citation></ref><ref id="jmv70195-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="jmv70195-cit-0005">
<string-name>
<given-names>X.&#x02010;Y.</given-names>
<surname>Li</surname>
</string-name>, <string-name>
<given-names>G.</given-names>
<surname>Li</surname>
</string-name>, <string-name>
<given-names>T.&#x02010;T.</given-names>
<surname>Gong</surname>
</string-name>, et al., &#x0201c;<article-title>Non&#x02010;Genetic Factors and Risk of Cervical Cancer: An Umbrella Review of Systematic Reviews and Meta&#x02010;Analyses of Observational Studies</article-title>,&#x0201d; <source>International Journal of Public Health</source>
<volume>68</volume> (<year>2023</year>): <elocation-id>1605198</elocation-id>, <ext-link xlink:href="https://www.ssph-journal.org/articles/10.3389/ijph.2023.1605198/full" ext-link-type="uri">https://www.ssph-journal.org/articles/10.3389/ijph.2023.1605198/full</ext-link>.<pub-id pub-id-type="pmid">37065642</pub-id>
</mixed-citation></ref><ref id="jmv70195-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="jmv70195-cit-0006">
<string-name>
<given-names>D.</given-names>
<surname>Ramachandran</surname>
</string-name> and <string-name>
<given-names>T.</given-names>
<surname>D&#x000f6;rk</surname>
</string-name>, &#x0201c;<article-title>Genomic Risk Factors for Cervical Cancer</article-title>,&#x0201d; <source>Cancers</source>
<volume>13</volume> (<year>2021</year>): <fpage>5137</fpage>, <ext-link xlink:href="https://www.mdpi.com/2072-6694/13/20/5137" ext-link-type="uri">https://www.mdpi.com/2072-6694/13/20/5137</ext-link>.<pub-id pub-id-type="pmid">34680286</pub-id>
</mixed-citation></ref><ref id="jmv70195-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="jmv70195-cit-0007">
<string-name>
<given-names>D.</given-names>
<surname>Chen</surname>
</string-name>, <string-name>
<given-names>I.</given-names>
<surname>Juko&#x02010;Pecirep</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Hammer</surname>
</string-name>, et al., &#x0201c;<article-title>Genome&#x02010;Wide Association Study of Susceptibility Loci for Cervical Cancer</article-title>,&#x0201d; <source>JNCI: Journal of the National Cancer Institute</source>
<volume>105</volume> (<year>2013</year>): <fpage>624</fpage>&#x02013;<lpage>633</lpage>. <ext-link xlink:href="https://academic.oup.com/jnci/article-lookup/doi/10.1093/jnci/djt051" ext-link-type="uri">https://academic.oup.com/jnci/article-lookup/doi/10.1093/jnci/djt051</ext-link>.<pub-id pub-id-type="pmid">23482656</pub-id>
</mixed-citation></ref><ref id="jmv70195-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="jmv70195-cit-0008">
<string-name>
<given-names>Y.</given-names>
<surname>Shi</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Li</surname>
</string-name>, <string-name>
<given-names>Z.</given-names>
<surname>Hu</surname>
</string-name>, et al., &#x0201c;<article-title>A Genome&#x02010;Wide Association Study Identifies Two New Cervical Cancer Susceptibility Loci at 4q12 and 17q12</article-title>,&#x0201d; <source>Nature Genetics</source>
<volume>45</volume> (<year>2013</year>): <fpage>918</fpage>&#x02013;<lpage>922</lpage>.<pub-id pub-id-type="pmid">23817570</pub-id>
</mixed-citation></ref><ref id="jmv70195-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="jmv70195-cit-0009">
<string-name>
<given-names>P. J.</given-names>
<surname>Leo</surname>
</string-name>, <string-name>
<given-names>M. M.</given-names>
<surname>Madeleine</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Wang</surname>
</string-name>, et al., &#x0201c;<article-title>Defining the Genetic Susceptibility to Cervical Neoplasia&#x02010;A Genome&#x02010;Wide Association Study</article-title>,&#x0201d; <source>PLoS Genetics</source>
<volume>13</volume> (<year>2017</year>): <elocation-id>e1006866</elocation-id>.<pub-id pub-id-type="pmid">28806749</pub-id>
</mixed-citation></ref><ref id="jmv70195-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="jmv70195-cit-0010">
<string-name>
<given-names>S. R.</given-names>
<surname>Rashkin</surname>
</string-name>, <string-name>
<given-names>R. E.</given-names>
<surname>Graff</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Kachuri</surname>
</string-name>, et al., &#x0201c;<article-title>Pan&#x02010;Cancer Study Detects Genetic Risk Variants and Shared Genetic Basis in Two Large Cohorts</article-title>,&#x0201d; <source>Nature Communications</source>
<volume>11</volume>, no. <issue>1</issue> (<year>2020</year>): <elocation-id>4423</elocation-id>, <pub-id pub-id-type="doi">10.1038/s41467-020-18246-6</pub-id>.</mixed-citation></ref><ref id="jmv70195-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="jmv70195-cit-0011">
<string-name>
<given-names>S. J.</given-names>
<surname>Bowden</surname>
</string-name>, <string-name>
<given-names>B.</given-names>
<surname>Bodinier</surname>
</string-name>, <string-name>
<given-names>I.</given-names>
<surname>Kalliala</surname>
</string-name>, et al., &#x0201c;<article-title>Genetic Variation in Cervical Preinvasive and Invasive Disease: A Genome&#x02010;Wide Association Study</article-title>,&#x0201d; <source>Lancet Oncology</source>
<volume>22</volume> (<year>2021</year>): <fpage>548</fpage>&#x02013;<lpage>557</lpage>, <pub-id pub-id-type="doi">10.1016/S1470-2045(21)00028-0</pub-id>.<pub-id pub-id-type="pmid">33794208</pub-id>
</mixed-citation></ref><ref id="jmv70195-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="jmv70195-cit-0012">
<string-name>
<given-names>M.</given-names>
<surname>Koel</surname>
</string-name>, <string-name>
<given-names>U.</given-names>
<surname>V&#x000f5;sa</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>J&#x000f5;eloo</surname>
</string-name>, et al., &#x0201c;<article-title>Gwas Meta&#x02010;Analyses Clarify the Genetics of Cervical Phenotypes and Inform Risk Stratification for Cervical Cancer</article-title>,&#x0201d; <source>Human Molecular Genetics</source>
<volume>32</volume> (<year>2023</year>): <fpage>2103</fpage>&#x02013;<lpage>2116</lpage>, <pub-id pub-id-type="doi">10.1093/hmg/ddad043</pub-id>.<pub-id pub-id-type="pmid">36929174</pub-id>
</mixed-citation></ref><ref id="jmv70195-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="jmv70195-cit-0013">
<string-name>
<given-names>R.</given-names>
<surname>Eisenbl&#x000e4;tter</surname>
</string-name>, <string-name>
<given-names>F.</given-names>
<surname>Seifert</surname>
</string-name>, <string-name>
<given-names>P.</given-names>
<surname>Sch&#x000fc;rmann</surname>
</string-name>, et al., &#x0201c;<article-title>Validation and Functional Follow&#x02010;Up of Cervical Cancer Risk Variants at the HLA Locus</article-title>,&#x0201d; <source>HLA</source>
<volume>104</volume>, no. <issue>2</issue> (<year>2024</year>): <elocation-id>e15597</elocation-id>, <pub-id pub-id-type="doi">10.1111/tan.15597</pub-id>.<pub-id pub-id-type="pmid">39101335</pub-id>
</mixed-citation></ref><ref id="jmv70195-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="jmv70195-cit-0014">
<string-name>
<given-names>D.</given-names>
<surname>Chen</surname>
</string-name>, <string-name>
<given-names>J. D.</given-names>
<surname>McKay</surname>
</string-name>, <string-name>
<given-names>G.</given-names>
<surname>Clifford</surname>
</string-name>, et al., &#x0201c;<article-title>Genome&#x02010;Wide Association Study of HPV Seropositivity</article-title>,&#x0201d; <source>Human Molecular Genetics</source>
<volume>20</volume> (<year>2011</year>): <fpage>4714</fpage>&#x02013;<lpage>4723</lpage>.<pub-id pub-id-type="pmid">21896673</pub-id>
</mixed-citation></ref><ref id="jmv70195-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="jmv70195-cit-0015">
<string-name>
<given-names>F.</given-names>
<surname>Seifert</surname>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Eisenbl&#x000e4;tter</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Beckmann</surname>
</string-name>, et al., &#x0201c;<article-title>Association of Two Genomic Variants With HPV Type&#x02010;Specific Risk of Cervical Cancer</article-title>,&#x0201d; <source>Tumour Virus Research</source>
<volume>16</volume> (<year>2023</year>): <elocation-id>200269</elocation-id>, <pub-id pub-id-type="doi">10.22541/au.167931548.89005454/v1</pub-id>.<pub-id pub-id-type="pmid">37499979</pub-id>
</mixed-citation></ref><ref id="jmv70195-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="jmv70195-cit-0016">
<string-name>
<given-names>L.</given-names>
<surname>Kachuri</surname>
</string-name>, <string-name>
<given-names>S. S.</given-names>
<surname>Francis</surname>
</string-name>, <string-name>
<given-names>M. L.</given-names>
<surname>Morrison</surname>
</string-name>, et al., &#x0201c;<article-title>The Landscape of Host Genetic Factors Involved in Immune Response to Common Viral Infections</article-title>,&#x0201d; <source>Genome Medicine</source>
<volume>12</volume> (<year>2020</year>): <fpage>93</fpage>.<pub-id pub-id-type="pmid">33109261</pub-id>
</mixed-citation></ref><ref id="jmv70195-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="jmv70195-cit-0017">
<string-name>
<given-names>A. J.</given-names>
<surname>Mentzer</surname>
</string-name>, <string-name>
<given-names>N.</given-names>
<surname>Brenner</surname>
</string-name>, <string-name>
<given-names>N.</given-names>
<surname>Allen</surname>
</string-name>, et al., &#x0201c;<article-title>Identification of Host&#x02013;Pathogen&#x02010;Disease Relationships Using a Scalable Multiplex Serology Platform in UK Biobank</article-title>,&#x0201d; <source>Nature Communications</source>
<volume>13</volume> (<year>2022</year>): <fpage>1818</fpage>.</mixed-citation></ref><ref id="jmv70195-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="jmv70195-cit-0018">
<string-name>
<given-names>D.</given-names>
<surname>Ramachandran</surname>
</string-name>, <string-name>
<given-names>P.</given-names>
<surname>Sch&#x000fc;rmann</surname>
</string-name>, <string-name>
<given-names>Q.</given-names>
<surname>Mao</surname>
</string-name>, et al., &#x0201c;<article-title>Association of Genomic Variants at the Human Leukocyte Antigen Locus with Cervical Cancer Risk, HPV Status and Gene Expression Levels</article-title>,&#x0201d; <source>International Journal of Cancer</source>
<volume>147</volume> (<year>2020</year>): <fpage>2458</fpage>&#x02013;<lpage>2468</lpage>.<pub-id pub-id-type="pmid">32580243</pub-id>
</mixed-citation></ref><ref id="jmv70195-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="jmv70195-cit-0019">
<string-name>
<given-names>K.</given-names>
<surname>Watanabe</surname>
</string-name>, <string-name>
<given-names>E.</given-names>
<surname>Taskesen</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Van Bochoven</surname>
</string-name>, and <string-name>
<given-names>D.</given-names>
<surname>Posthuma</surname>
</string-name>, &#x0201c;<article-title>Functional Mapping and Annotation of Genetic Associations With FUMA</article-title>,&#x0201d; <source>Nature Communications</source>
<volume>8</volume> (<year>2017</year>): <fpage>1826</fpage>, <pub-id pub-id-type="doi">10.1038/s41467-017-01261-5</pub-id>.</mixed-citation></ref><ref id="jmv70195-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="jmv70195-cit-0020">
<string-name>
<given-names>C. A.</given-names>
<surname>de Leeuw</surname>
</string-name>, <string-name>
<given-names>J. M.</given-names>
<surname>Mooij</surname>
</string-name>, <string-name>
<given-names>T.</given-names>
<surname>Heskes</surname>
</string-name>, and <string-name>
<given-names>D.</given-names>
<surname>Posthuma</surname>
</string-name>, &#x0201c;<article-title>MAGMA: Generalized Gene&#x02010;Set Analysis of GWAS Data</article-title>,&#x0201d; <source>PLoS Computational Biology</source>
<volume>11</volume> (<year>2015</year>): <elocation-id>e1004219</elocation-id>.<pub-id pub-id-type="pmid">25885710</pub-id>
</mixed-citation></ref><ref id="jmv70195-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="jmv70195-cit-0021">
<string-name>
<given-names>G.</given-names>
<surname>Wang</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Sarkar</surname>
</string-name>, <string-name>
<given-names>P.</given-names>
<surname>Carbonetto</surname>
</string-name>, and <string-name>
<given-names>M.</given-names>
<surname>Stephens</surname>
</string-name>, &#x0201c;<article-title>A Simple New Approach to Variable Selection in Regression, With Application to Genetic Fine Mapping</article-title>,&#x0201d; <source>Journal of the Royal Statistical Society Series B: Statistical Methodology</source>
<volume>82</volume> (<year>2020</year>): <fpage>1273</fpage>&#x02013;<lpage>1300</lpage>, <pub-id pub-id-type="doi">10.1111/rssb.12388</pub-id>.<pub-id pub-id-type="pmid">37220626</pub-id>
</mixed-citation></ref><ref id="jmv70195-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="jmv70195-cit-0022">
<string-name>
<given-names>W.</given-names>
<surname>Zhang</surname>
</string-name>, <string-name>
<given-names>T.</given-names>
<surname>Lu</surname>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Sladek</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Dupuis</surname>
</string-name>, and <string-name>
<given-names>G.</given-names>
<surname>Lettre</surname>
</string-name>, &#x0201c;<article-title>Robust Fine&#x02010;Mapping in the Presence of Linkage Disequilibrium Mismatch</article-title>,&#x0201d; <source>bioRxiv</source> (<year>2024</year>): <ext-link xlink:href="http://biorxiv.org/content/early/2024/11/03/2024.10.29.620968.abstract" ext-link-type="uri">http://biorxiv.org/content/early/2024/11/03/2024.10.29.620968.abstract</ext-link>.</mixed-citation></ref><ref id="jmv70195-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="jmv70195-cit-0023">
<string-name>
<given-names>L. D.</given-names>
<surname>Ward</surname>
</string-name> and <string-name>
<given-names>M.</given-names>
<surname>Kellis</surname>
</string-name>, &#x0201c;<article-title>HaploReg: A Resource for Exploring Chromatin States, Conservation, and Regulatory Motif Alterations Within Sets of Genetically Linked Variants</article-title>,&#x0201d; <source>Nucleic Acids Research</source>
<volume>40</volume> (<year>2012</year>): <fpage>D930</fpage>&#x02013;<lpage>D934</lpage>.<pub-id pub-id-type="pmid">22064851</pub-id>
</mixed-citation></ref><ref id="jmv70195-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="jmv70195-cit-0024">
<string-name>
<given-names>A. P.</given-names>
<surname>Boyle</surname>
</string-name>, <string-name>
<given-names>E. L.</given-names>
<surname>Hong</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Hariharan</surname>
</string-name>, et al., &#x0201c;<article-title>Annotation of Functional Variation in Personal Genomes Using RegulomeDB</article-title>,&#x0201d; <source>Genome Research</source>
<volume>22</volume> (<year>2012</year>): <fpage>1790</fpage>&#x02013;<lpage>1797</lpage>.<pub-id pub-id-type="pmid">22955989</pub-id>
</mixed-citation></ref><ref id="jmv70195-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="jmv70195-cit-0025">
<string-name>
<given-names>C. E.</given-names>
<surname>Breeze</surname>
</string-name>, <string-name>
<given-names>E.</given-names>
<surname>Haugen</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Gutierrez&#x02010;Arcelus</surname>
</string-name>, et al., &#x0201c;<article-title>ForgeDB: A Tool for Identifying Candidate Functional Variants and Uncovering Target Genes and Mechanisms for Complex Diseases</article-title>,&#x0201d; <source>Genome Biology</source>
<volume>25</volume> (<year>2024</year>): <fpage>1</fpage>&#x02013;<lpage>13</lpage>, <pub-id pub-id-type="doi">10.1186/s13059-023-03126-1</pub-id>.<pub-id pub-id-type="pmid">38167462</pub-id>
</mixed-citation></ref><ref id="jmv70195-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="jmv70195-cit-0026">
<string-name>
<given-names>T. L.</given-names>
<surname>Bailey</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Boden</surname>
</string-name>, <string-name>
<given-names>F. A.</given-names>
<surname>Buske</surname>
</string-name>, et al., &#x0201c;<article-title>MEME Suite: Tools for Motif Discovery and Searching</article-title>,&#x0201d; <source>Nucleic Acids Research</source>
<volume>37</volume> (<year>2009</year>): <fpage>W202</fpage>&#x02013;<lpage>W208</lpage>.<pub-id pub-id-type="pmid">19458158</pub-id>
</mixed-citation></ref><ref id="jmv70195-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="jmv70195-cit-0027">
<string-name>
<given-names>B. J.</given-names>
<surname>Schmiedel</surname>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Singh</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Madrigal</surname>
</string-name>, et al., &#x0201c;<article-title>Impact of Genetic Polymorphisms on Human Immune Cell Gene Expression</article-title>,&#x0201d; <source>Cell</source>
<volume>175</volume> (<year>2018</year>): <fpage>1701</fpage>&#x02013;<lpage>1715.e16</lpage>, <ext-link xlink:href="https://www.sciencedirect.com/science/article/pii/S009286741831331X" ext-link-type="uri">https://www.sciencedirect.com/science/article/pii/S009286741831331X</ext-link>.<pub-id pub-id-type="pmid">30449622</pub-id>
</mixed-citation></ref><ref id="jmv70195-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="jmv70195-cit-0028">
<string-name>
<given-names>B.</given-names>
<surname>Smith</surname>
</string-name>, <string-name>
<given-names>Z.</given-names>
<surname>Chen</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Reimers</surname>
</string-name>, et al., &#x0201c;<article-title>Sequence Imputation of HPV16 Genomes for Genetic Association Studies</article-title>,&#x0201d; <source>PLoS One</source>
<volume>6</volume> (<year>2011</year>): <elocation-id>e21375</elocation-id>.<pub-id pub-id-type="pmid">21731721</pub-id>
</mixed-citation></ref><ref id="jmv70195-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="jmv70195-cit-0029">
<string-name>
<given-names>K.</given-names>
<surname>Odunsi</surname>
</string-name>, <string-name>
<given-names>G.</given-names>
<surname>Terry</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Ho</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Bell</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Cuzick</surname>
</string-name>, and <string-name>
<given-names>T. S.</given-names>
<surname>Ganesan</surname>
</string-name>, &#x0201c;<article-title>Association Between HLA DQBL * 03 and Cervical Intra&#x02010;Epithelial Neoplasia</article-title>,&#x0201d; <source>Molecular Medicine</source>
<volume>1</volume> (<year>1995</year>): <fpage>161</fpage>&#x02013;<lpage>171</lpage>.<pub-id pub-id-type="pmid">8529095</pub-id>
</mixed-citation></ref><ref id="jmv70195-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="jmv70195-cit-0030">
<string-name>
<given-names>R.</given-names>
<surname>Chambuso</surname>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Ramesar</surname>
</string-name>, <string-name>
<given-names>E.</given-names>
<surname>Kaambo</surname>
</string-name>, et al., &#x0201c;<article-title>Human Leukocyte Antigen (HLA) Class II &#x02010;DRB1 and &#x02010;DQB1 Alleles and the Association With Cervical Cancer in HIV/HPV Co&#x02010;Infected Women in South Africa</article-title>,&#x0201d; <source>Journal of Cancer</source>
<volume>10</volume> (<year>2019</year>): <fpage>2145</fpage>&#x02013;<lpage>2152</lpage>.<pub-id pub-id-type="pmid">31258717</pub-id>
</mixed-citation></ref><ref id="jmv70195-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="jmv70195-cit-0031">
<string-name>
<given-names>X.</given-names>
<surname>Zhang</surname>
</string-name>, <string-name>
<given-names>Z.</given-names>
<surname>Lv</surname>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Yu</surname>
</string-name>, <string-name>
<given-names>F.</given-names>
<surname>Wang</surname>
</string-name>, and <string-name>
<given-names>J.</given-names>
<surname>Zhu</surname>
</string-name>, &#x0201c;<article-title>The HLA&#x02010;DQB1 Gene Polymorphisms Associated With Cervical Cancer Risk: A Meta&#x02010;Analysis</article-title>,&#x0201d; <source>Biomedicine &#x00026; Pharmacotherapy</source>
<volume>73</volume> (<year>2015</year>): <fpage>58</fpage>&#x02013;<lpage>64</lpage>.<pub-id pub-id-type="pmid">26211583</pub-id>
</mixed-citation></ref><ref id="jmv70195-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="jmv70195-cit-0032">
<string-name>
<given-names>M. K.</given-names>
<surname>Halle</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>S&#x000f8;dal</surname>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Forsse</surname>
</string-name>, et al., &#x0201c;<article-title>A 10&#x02010;Gene Prognostic Signature Points to LIMCH1 and HLA&#x02010;DQB1 as Important Players in Aggressive Cervical Cancer Disease</article-title>,&#x0201d; <source>British Journal of Cancer</source>
<volume>124</volume> (<year>2021</year>): <fpage>1690</fpage>&#x02013;<lpage>1698</lpage>.<pub-id pub-id-type="pmid">33723390</pub-id>
</mixed-citation></ref><ref id="jmv70195-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="jmv70195-cit-0033">
<string-name>
<given-names>H.</given-names>
<surname>Wang</surname>
</string-name>, <string-name>
<given-names>B.</given-names>
<surname>Yang</surname>
</string-name>, <string-name>
<given-names>X.</given-names>
<surname>Cai</surname>
</string-name>, et al., &#x0201c;<article-title>Hepatocellular Carcinoma Risk Variant Modulates lncRNA HLA&#x02010;DQB1&#x02010;AS1 Expression via a Long&#x02010;Range Enhancer&#x02013;Promoter Interaction</article-title>,&#x0201d; <source>Carcinogenesis</source>
<volume>42</volume> (<year>2021</year>): <fpage>1347</fpage>&#x02013;<lpage>1356</lpage>, <pub-id pub-id-type="doi">10.1093/carcin/bgab095</pub-id>.<pub-id pub-id-type="pmid">34665859</pub-id>
</mixed-citation></ref><ref id="jmv70195-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="jmv70195-cit-0034">
<string-name>
<given-names>J.</given-names>
<surname>Long</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Liu</surname>
</string-name>, <string-name>
<given-names>X.</given-names>
<surname>Zhou</surname>
</string-name>, <string-name>
<given-names>X.</given-names>
<surname>Lu</surname>
</string-name>, and <string-name>
<given-names>L.</given-names>
<surname>Qin</surname>
</string-name>, &#x0201c;<article-title>HLA&#x02010;DQB1&#x02010;AS1 Promotes Cell Proliferation, Inhibits Apoptosis, and Binds with ZRANB2 Protein in Hepatocellular Carcinoma</article-title>,&#x0201d; <source>Journal of Oncology</source>
<volume>2022</volume> (<year>2022</year>): <elocation-id>7130634</elocation-id>.<pub-id pub-id-type="pmid">35602293</pub-id>
</mixed-citation></ref><ref id="jmv70195-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="jmv70195-cit-0035">
<string-name>
<given-names>H.</given-names>
<surname>Chen</surname>
</string-name>, <string-name>
<given-names>T.</given-names>
<surname>Wang</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Huang</surname>
</string-name>, and <string-name>
<given-names>P.</given-names>
<surname>Zeng</surname>
</string-name>, &#x0201c;<article-title>New Novel Non&#x02010;MHC Genes Were Identified for Cervical Cancer With an Integrative Analysis Approach of Transcriptome&#x02010;Wide Association Study</article-title>,&#x0201d; <source>Journal of Cancer</source>
<volume>12</volume> (<year>2021</year>): <fpage>840</fpage>&#x02013;<lpage>848</lpage>.<pub-id pub-id-type="pmid">33403041</pub-id>
</mixed-citation></ref><ref id="jmv70195-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="jmv70195-cit-0036">
<string-name>
<given-names>A. B.</given-names>
<surname>Kamiza</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Kamiza</surname>
</string-name>, and <string-name>
<given-names>C. G.</given-names>
<surname>Mathew</surname>
</string-name>, &#x0201c;<article-title>HLA&#x02010;DRB1 Alleles and Cervical Cancer: A Meta&#x02010;Analysis of 36 Case&#x02010;Control Studies</article-title>,&#x0201d; <source>Cancer Epidemiology</source>
<volume>67</volume> (<year>2020</year>): <elocation-id>101748</elocation-id>, <pub-id pub-id-type="doi">10.1016/j.canep.2020.101748</pub-id>.<pub-id pub-id-type="pmid">32562888</pub-id>
</mixed-citation></ref><ref id="jmv70195-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="jmv70195-cit-0037">
<string-name>
<given-names>X.</given-names>
<surname>Bao</surname>
</string-name>, <string-name>
<given-names>A. L.</given-names>
<surname>Hanson</surname>
</string-name>, <string-name>
<given-names>M. M.</given-names>
<surname>Madeleine</surname>
</string-name>, et al., &#x0201c;<article-title>HLA and KIR Associations of Cervical Neoplasia</article-title>,&#x0201d; <source>The Journal of Infectious Diseases</source>
<volume>218</volume> (<year>2018</year>): <fpage>2006</fpage>&#x02013;<lpage>2015</lpage>.<pub-id pub-id-type="pmid">30099516</pub-id>
</mixed-citation></ref><ref id="jmv70195-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="jmv70195-cit-0038">
<string-name>
<given-names>M.</given-names>
<surname>Gojobori</surname>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Mashiba</surname>
</string-name>, <string-name>
<given-names>K.</given-names>
<surname>Matsunaga</surname>
</string-name>, and <string-name>
<given-names>S.</given-names>
<surname>Jimi</surname>
</string-name>, &#x0201c;<article-title>Serum Complement Levels in Uterine Cervical Cancer Patients and Their Relationship to Cell&#x02010;Mediated Immunity</article-title>,&#x0201d; <source>Japanese Journal of Clinical Oncology</source>
<volume>11</volume> (<year>1981</year>): <fpage>101</fpage>&#x02013;<lpage>108</lpage>. <ext-link xlink:href="https://academic.oup.com/jjco/article/11/1/101/907836/Serum-Complement-Levels-in-Uterine-Cervical-Cancer" ext-link-type="uri">https://academic.oup.com/jjco/article/11/1/101/907836/Serum-Complement-Levels-in-Uterine-Cervical-Cancer</ext-link>.</mixed-citation></ref><ref id="jmv70195-bib-0039"><label>39</label><mixed-citation publication-type="journal" id="jmv70195-cit-0039">
<string-name>
<given-names>D.</given-names>
<surname>Chen</surname>
</string-name> and <string-name>
<given-names>U.</given-names>
<surname>Gyllensten</surname>
</string-name>, &#x0201c;<article-title>Systematic Investigation of Contribution of Genetic Variation in the HLA&#x02010;DP Region to Cervical Cancer Susceptibility</article-title>,&#x0201d; <source>Carcinogenesis</source>
<volume>35</volume> (<year>2014</year>): <fpage>1765</fpage>&#x02013;<lpage>1769</lpage>.<pub-id pub-id-type="pmid">24743517</pub-id>
</mixed-citation></ref><ref id="jmv70195-bib-0040"><label>40</label><mixed-citation publication-type="journal" id="jmv70195-cit-0040">
<string-name>
<given-names>L.</given-names>
<surname>Cheng</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Guo</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Zhan</surname>
</string-name>, and <string-name>
<given-names>P.</given-names>
<surname>Xia</surname>
</string-name>, &#x0201c;<article-title>Association Between HLA&#x02010;DP Gene Polymorphisms and Cervical Cancer Risk: A Meta&#x02010;Analysis</article-title>,&#x0201d; <source>BioMed Research International</source>
<volume>2018</volume> (<year>2018</year>): <fpage>1</fpage>&#x02013;<lpage>13</lpage>.</mixed-citation></ref><ref id="jmv70195-bib-0041"><label>41</label><mixed-citation publication-type="journal" id="jmv70195-cit-0041">
<string-name>
<given-names>X.</given-names>
<surname>Dong</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Yang</surname>
</string-name>, <string-name>
<given-names>Z.</given-names>
<surname>Zou</surname>
</string-name>, et al., &#x0201c;<article-title>Sorting Nexin 5 Mediates Virus&#x02010;Induced Autophagy and Immunity</article-title>,&#x0201d; <source>Nature</source>
<volume>589</volume> (<year>2021</year>): <fpage>456</fpage>&#x02013;<lpage>461</lpage>.<pub-id pub-id-type="pmid">33328639</pub-id>
</mixed-citation></ref><ref id="jmv70195-bib-0042"><label>42</label><mixed-citation publication-type="journal" id="jmv70195-cit-0042">
<string-name>
<given-names>J.</given-names>
<surname>Cai</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Sun</surname>
</string-name>, <string-name>
<given-names>B.</given-names>
<surname>Hu</surname>
</string-name>, et al., &#x0201c;<article-title>Sorting Nexin 5 Controls Head and Neck Squamous Cell Carcinoma Progression by Modulating FBW7</article-title>,&#x0201d; <source>Journal of Cancer</source>
<volume>10</volume> (<year>2019</year>): <fpage>2942</fpage>&#x02013;<lpage>2952</lpage>.<pub-id pub-id-type="pmid">31281471</pub-id>
</mixed-citation></ref><ref id="jmv70195-bib-0043"><label>43</label><mixed-citation publication-type="journal" id="jmv70195-cit-0043">
<string-name>
<given-names>J.</given-names>
<surname>Liang</surname>
</string-name>, <string-name>
<given-names>G.</given-names>
<surname>Li</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Liao</surname>
</string-name>, et al., &#x0201c;<article-title>Non&#x02010;Coding Small Nucleolar RNA SNORD17 Promotes the Progression of Hepatocellular Carcinoma Through a Positive Feedback Loop Upon p53 Inactivation</article-title>,&#x0201d; <source>Cell Death &#x00026; Differentiation</source>
<volume>29</volume> (<year>2022</year>): <fpage>988</fpage>&#x02013;<lpage>1003</lpage>, <pub-id pub-id-type="doi">10.1038/s41418-022-00929-w</pub-id>.<pub-id pub-id-type="pmid">35034103</pub-id>
</mixed-citation></ref><ref id="jmv70195-bib-0044"><label>44</label><mixed-citation publication-type="journal" id="jmv70195-cit-0044">
<string-name>
<given-names>C.</given-names>
<surname>Lesseur</surname>
</string-name>, <string-name>
<given-names>B.</given-names>
<surname>Diergaarde</surname>
</string-name>, <string-name>
<given-names>A. F.</given-names>
<surname>Olshan</surname>
</string-name>, et al., &#x0201c;<article-title>Genome&#x02010;Wide Association Analyses Identify New Susceptibility Loci for Oral Cavity and Pharyngeal Cancer</article-title>,&#x0201d; <source>Nature Genetics</source>
<volume>48</volume> (<year>2016</year>): <fpage>1544</fpage>&#x02013;<lpage>1550</lpage>.<pub-id pub-id-type="pmid">27749845</pub-id>
</mixed-citation></ref><ref id="jmv70195-bib-0045"><label>45</label><mixed-citation publication-type="journal" id="jmv70195-cit-0045">
<string-name>
<given-names>X.</given-names>
<surname>Li</surname>
</string-name>, <string-name>
<given-names>X.</given-names>
<surname>Wu</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Li</surname>
</string-name>, et al., &#x0201c;<article-title>Promoter Hypermethylation of SOX11 Promotes the Progression of Cervical Cancer In Vitro and In Vivo</article-title>,&#x0201d; <source>Oncology Reports</source>
<volume>41</volume> (<year>2019</year>): <fpage>2351</fpage>&#x02013;<lpage>2360</lpage>.<pub-id pub-id-type="pmid">30720133</pub-id>
</mixed-citation></ref><ref id="jmv70195-bib-0046"><label>46</label><mixed-citation publication-type="journal" id="jmv70195-cit-0046">
<string-name>
<given-names>J. E.</given-names>
<surname>Apasu</surname>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Schuette</surname>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>LaRanger</surname>
</string-name>, et al., &#x0201c;<article-title>Neuronal Calcium Sensor 1 (NCS1) Promotes Motility and Metastatic Spread of Breast Cancer Cells In Vitro and In Vivo</article-title>,&#x0201d; <source>The FASEB Journal</source>
<volume>33</volume> (<year>2019</year>): <fpage>4802</fpage>&#x02013;<lpage>4813</lpage>.<pub-id pub-id-type="pmid">30592625</pub-id>
</mixed-citation></ref><ref id="jmv70195-bib-0047"><label>47</label><mixed-citation publication-type="journal" id="jmv70195-cit-0047">
<string-name>
<given-names>E. T.</given-names>
<surname>Kim</surname>
</string-name>, <string-name>
<given-names>J. M.</given-names>
<surname>Dybas</surname>
</string-name>, <string-name>
<given-names>K.</given-names>
<surname>Kulej</surname>
</string-name>, et al., &#x0201c;<article-title>Comparative Proteomics Identifies Schlafen 5 (SLFN5) as a Herpes Simplex Virus Restriction Factor That Suppresses Viral Transcription</article-title>,&#x0201d; <source>Nature Microbiology</source>
<volume>6</volume> (<year>2021</year>): <fpage>234</fpage>&#x02013;<lpage>245</lpage>. <ext-link xlink:href="https://www.nature.com/articles/s41564-020-00826-3" ext-link-type="uri">https://www.nature.com/articles/s41564-020-00826-3</ext-link>.</mixed-citation></ref><ref id="jmv70195-bib-0048"><label>48</label><mixed-citation publication-type="journal" id="jmv70195-cit-0048">
<string-name>
<given-names>J.</given-names>
<surname>Ding</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Wang</surname>
</string-name>, <string-name>
<given-names>Z.</given-names>
<surname>Wang</surname>
</string-name>, et al., &#x0201c;<article-title>Schlafen 5 Suppresses Human Immunodeficiency Virus Type 1 Transcription by Commandeering Cellular Epigenetic Machinery</article-title>,&#x0201d; <source>Nucleic Acids Research</source>
<volume>50</volume> (<year>2022</year>): <fpage>6137</fpage>&#x02013;<lpage>6153</lpage>.<pub-id pub-id-type="pmid">35687115</pub-id>
</mixed-citation></ref><ref id="jmv70195-bib-0049"><label>49</label><mixed-citation publication-type="journal" id="jmv70195-cit-0049">
<string-name>
<given-names>S.</given-names>
<surname>Miyauchi</surname>
</string-name>, <string-name>
<given-names>S. S.</given-names>
<surname>Kim</surname>
</string-name>, <string-name>
<given-names>R. N.</given-names>
<surname>Jones</surname>
</string-name>, et al., &#x0201c;<article-title>Human Papillomavirus E5 Suppresses Immunity via Inhibition of the Immunoproteasome and STING Pathway</article-title>,&#x0201d; <source>Cell Reports</source>
<volume>42</volume> (<year>2023</year>): <elocation-id>112508</elocation-id>, <pub-id pub-id-type="doi">10.1016/j.celrep.2023.112508</pub-id>.<pub-id pub-id-type="pmid">37171962</pub-id>
</mixed-citation></ref><ref id="jmv70195-bib-0050"><label>50</label><mixed-citation publication-type="journal" id="jmv70195-cit-0050">
<string-name>
<given-names>G.</given-names>
<surname>Wan</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Zhu</surname>
</string-name>, <string-name>
<given-names>X.</given-names>
<surname>Gu</surname>
</string-name>, et al., &#x0201c;<article-title>Human Schlafen 5 Regulates Reversible Epithelial and Mesenchymal Transitions in Breast Cancer by Suppression of ZEB1 Transcription</article-title>,&#x0201d; <source>British Journal of Cancer</source>
<volume>123</volume> (<year>2020</year>): <fpage>633</fpage>&#x02013;<lpage>643</lpage>.<pub-id pub-id-type="pmid">32488136</pub-id>
</mixed-citation></ref><ref id="jmv70195-bib-0051"><label>51</label><mixed-citation publication-type="journal" id="jmv70195-cit-0051">
<string-name>
<given-names>S.</given-names>
<surname>Al&#x02010;Marsoummi</surname>
</string-name>, <string-name>
<given-names>E. E.</given-names>
<surname>Vomhof&#x02010;DeKrey</surname>
</string-name>, and <string-name>
<given-names>M. D.</given-names>
<surname>Basson</surname>
</string-name>, &#x0201c;<article-title>Schlafens: Emerging Proteins in Cancer Cell Biology</article-title>,&#x0201d; <source>Cells</source>
<volume>10</volume> (<year>2021</year>): <fpage>2238</fpage>.<pub-id pub-id-type="pmid">34571887</pub-id>
</mixed-citation></ref></ref-list></back></article>